

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

09th December, 2025

To,
The Manager,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 539206; Company Symbol: GVBL

Sub: Compliance Under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Annual Report for The Financial Year 2024-25.

Dear Sir/Madam,

Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Annual Report of the Company for the Financial Year 2024-25, along with the Notice of Annual General Meeting (AGM) scheduled to be held on Wednesday, the 31st day of December, 2025 at 09:00 A.M. through Physical Mean.

The soft copies of the Annual Report are being dispatched today electronically to those Members whose email IDs are registered with the Company/Depositories and RTA of the Company as on cutoff date i.e. 05th December, 2025.

This is for your information and record please.

Thanking you,
Yours sincerely,

For Genomic Valley Biotech Limited

**Yogesh Agrawal
Managing Director
DIN : 01165288**



31st ANNUAL REPORT

GENOMIC VALLEY


WHERE HEALTH MEETS INNOVATION

2024 - 2025

GENOMIC VALLEY BIOTECH LIMITED



The Chairman & Managing Director, Shri Yogesh Agrawal & his daughter Ojaswini Avantika with the then Prime Minister of India Hon'ble Shri Atal Bihari Vajpayee showing him gratitude for suggesting the name of the Company as "Genomic Valley".



PM asks scientists to create genomic valley

Our New Delhi Bureau
NEW DELHI 3 JANUARY



PRIME Minister Atal Behari Vajpayee today heralded the advent of the 'bioinformatics wave' in India. Ruing the fact that the country caught up with the Silicon Valley phenomenon rather late, he urged the bio-sciences and IT communities in the country to take the lead in creating the new 'Genomic Valley' of the 21st century.


Mr Vajpayee said bold and unconventional initiatives were needed to seize the big new opportunity arising out of the information generated by the human genome project. Armed with this 'base' information India could be in the vanguard of a new revolution as it had a vast human genetic diversity that would provide the 'knowledge of variation' required to establish an edge, he pointed out.

Inaugurating the 88th Indian Science Congress in New Delhi today, he added that such initiatives

needed huge investments which could not come from budgetary allocation alone and it was necessary to promote public-private partnerships. He, however, expressed concern over the demand and exodus of software professionals which was leading to a lack of enthusiasm for careers in other streams of science. Citing the proposal of a group of US-based entrepreneurs to set up global institutes of science and technology in India, he said the government would facilitate such initiatives.

While the private sector was responding to opportunities in the knowledge sector of late, pressing reforms were needed in the administration and governance to remove bureaucratic control and 'facilitate' science to flourish, he added. Reiterating that his government would hike investments in R&D from the 2 per cent of GDP, he underscored the earmarking of Rs 50 crore for the India Millennium Missions to be executed by the Technology Information Forecasting and Assessment Council (TIFAC) and an additional Rs 50 crore for the New Millennium Technology Leadership Initiatives by CSIR.

FESTIVAL OF GENOMICS - 2025



The Festival of Genomics & Biodata 2025 was a leading life sciences event held in London (January) and Boston (June), focusing on cutting-edge integrations of AI, multi-omics, and single-cell analysis.

Date: Jan 29-30, 2025

Place: London, UK

GENOMIC INDIA CONFERENCE - 2025



The Genomics India Conference (GIC) 2025 focused on the theme "The Indian Genomics Journey," featuring the first-ever "Biology in AI Era" symposium. It highlighted major initiatives like the 10K Genome India Project, bringing together over 60 speakers and 50+ organizations to discuss advancements in the field.

Date : Aug 12 -14, 2025

Place: Bangalore, India



CONTENTS

Particulars	Page No.
Table of Contents	04
About the Company- Our Mission and Vision	05
Our Services	08
The Process of How We Do It	11
From the Desk of the Chairman	13
Corporate Information	18
Notice of Annual general Meeting	19
Board Report	40
Management Discussion & Analysis Report	53
Secretarial Audit Report (MR-3)	62
Managing Director (MD) & Chief Financial Officer (CFO) Certification	66
Certificate of Non-Disqualification of Directors	67
Independent Auditor Report	69
Annual Financial Statements	83

About US

Welcome to Genomic Valley Biotech Ltd., where innovation meets expertise to revolutionize healthcare. With a dedicated team boasting over 10 years of experience in Next-Generation Sequencing (NGS), oncology, and Artificial Intelligence (AI), we are at the forefront of integrating advanced technologies into biotechnology and healthcare solutions.

Our team comprises highly skilled professionals passionate about utilizing their extensive knowledge to drive forward the fields of oncology research and diagnostics. We are committed to implementing both novel and validated methods, ensuring the delivery of accurate and confident results in our pursuit of better healthcare outcomes.

We are inspired by the visionary dream of India's former Prime Minister Shri Atal Bihari Vajpayee to create a Silicon Valley of genomics right here in India. We are on an exhilarating journey to transform this dream into reality by driving innovation and excellence in the field of genomics. Our mission is to establish Genomics Valley as a global epicenter for genomic research, diagnostics, and healthcare solutions, much like Silicon Valley has become for technology.

At Genomic Valley Biotech Ltd., we believe in the transformative power of AI and IT. By leveraging these cutting-edge technologies, we aim to enhance the precision, efficiency, and effectiveness of oncology diagnostics and research, ultimately contributing to a healthier future for all. Join us on our journey as we pave the way for innovative solutions in biotechnology and healthcare.

Our Mission



At Genomic Valley, our mission is to revolutionize healthcare by leveraging the power of genomics. We strive to offer accessible, reliable, and actionable genetic information that helps you understand your health better and take proactive steps towards well-being. By integrating Artificial Intelligence (AI) in healthcare and genomics, we aim to simplify the tasks of healthcare professionals, making diagnostics more accurate, treatments more personalized, and overall healthcare more efficient.



We are committed to providing affordable and cost-effective solutions that are easily available to our users. Our innovative approach significantly reduces the time taken for genetic analysis, thereby enabling doctors to make informed decisions swiftly and effectively. At Genomic Valley, we believe in making advanced healthcare accessible to everyone, empowering individuals and supporting healthcare professionals in delivering the best possible care.


Our Vision

At Genomic Valley, our vision is to revolutionize molecular diagnostics with precision and efficiency through AI-based approaches. We are dedicated to advancing healthcare by offering more accurate diagnostics, backed by comprehensive metadata, delivered in less time.

Our goal is to provide personalized therapy options, empowering doctors with robust decision-making support and identifying effective treatments. By harnessing AI and IT, we aim to transform oncology research and diagnostics, ensuring patients receive precise and timely care.

We envision a future where cutting-edge technology and human expertise converge to revolutionize molecular diagnostics. Our commitment to innovation drives us to continuously implement advanced methods, improving patient outcomes and advancing global healthcare.

We also provide comprehensive Research Process Outsourcing (RPO) services to global researchers. With a dedicated team and professional software tools, we ensure refined data analysis and optimal solutions, enhancing research projects with advanced analytical capabilities. Join us in shaping the future of diagnostics and treatment, where technology and healthcare work hand in hand to deliver unparalleled results.



Our Services

Diagnostic Services

At Genomic Valley Biotech Ltd., we harness Next-Generation Sequencing (NGS) and advanced AI technologies to deliver precise and rapid molecular diagnostics. This enables early detection and personalized treatment plans for oncology patients. Our cutting-edge NGS ensures healthcare providers have reliable data for informed decision-making, ultimately improving patient outcomes.

Research Services

At Genomic Valley Biotech Ltd., we advance oncology research using Next-Generation Sequencing (NGS) and artificial intelligence. With over a decade of experience, our team uncovers novel biomarkers and genetic insights. Collaborating with leading academic and industry partners, we translate discoveries into practical solutions. Our goal is to develop more effective diagnostic tools and therapeutic strategies, driving innovation and enhancing the understanding of cancer biology.



Diagnostic Services



Personalized Healthcare

At Genomic Valley Biotech Ltd., we tailor medical treatment to individual genetic profiles using Next-Generation Sequencing (NGS) and advanced AI. Our precise diagnostics enable healthcare providers to design customized treatment plans, enhancing therapy effectiveness, minimizing adverse effects, and ensuring optimal care for each patient's unique genetic makeup.

Genetic Disease Predisposition

Our genetic disease predisposition services identify susceptibility to hereditary conditions through NGS analysis. By predicting the likelihood of developing certain diseases, we enable early interventions and proactive healthcare measures. This empowers patients and healthcare professionals to make informed decisions about lifestyle changes, monitoring, and preventive strategies to mitigate genetic disease risks.



Community Health Support

At Genomic Valley Biotech Ltd., we improve public health outcomes through comprehensive genomic screening programs. Using NGS and AI, we offer population-wide genetic testing to identify health risks and tailor community health initiatives. This helps public health agencies design effective programs, improve disease prevention, and enhance community well-being.

Research Services



AI-Based Genome Healthcare

At Genomic Valley Biotech Ltd., we are pioneering AI-based genome healthcare research to revolutionize the way genetic data is analyzed and interpreted. By developing sophisticated AI algorithms and machine learning models, we enhance the accuracy and speed of genomic diagnostics and research. This approach allows us to uncover complex genetic patterns and associations, driving innovations in personalized medicine and therapeutic strategies.



Metagenomics and Healthcare


Our metagenomics research studies microbial communities' genomes and their impact on health and disease. Using advanced sequencing, we explore microbiomes' roles in health conditions to identify novel biomarkers and therapeutic targets. This research aims to transform our understanding and develop microbiome-based treatments and interventions.




Extramural Research Project

Our extramural research projects involve collaborating with external academic institutions, research organizations, and industry partners to advance genomic science. These projects leverage our expertise in NGS and AI to explore new frontiers in genetics and healthcare. Through these collaborations, we aim to accelerate the translation of scientific discoveries into practical applications that can benefit patients and the broader healthcare community.

The Process How We Do It





“

Taking Care of Your Tomorrow

”



Scan to Visit Website

Email:

support@genomicvalley.com

Address:

4 KM Stone, Berri Chhara Road,
P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar,
HARYANA, INDIA - 124 507

Connect With Us



From the Desk of the Chairman

How Next-Generation DNA Sequencing Can Change Our Lives

Dear Valued Shareholders,

It is an honor to address you at this year's annual meeting. As the Chairman of Genomic Valley Biotech Limited, I'm thrilled to share with you something that's revolutionizing our world: Next- Next-generation sequencing (NGS). NGS is an incredibly advanced technology that allows us to read and understand the DNA or RNA within our bodies with remarkable speed and precision. Think of it as a powerful tool that enables us to explore the intricate blueprint of life, unlocking details that were once beyond our reach.

Today, I want to shed light on how NGS is transforming our everyday lives. From advancing personalized healthcare and helping us understand our genetic makeup to solving crimes and unraveling the mysteries of our environment, NGS is becoming an indispensable part of our journey toward a better, healthier future.

NGS in Healthcare

- First, let's talk about healthcare. NGS is making a big difference here.
 - Imagine you have a health problem that doctors can't figure out. NGS can look at your DNA and find out what's wrong, even when other tests can't.
- **Personalized Medicine**
 - One of the most exciting applications of NGS can do is personalized medicine.
 - Usually, doctors give everyone the same treatment, but NGS lets doctors create treatments just for you based on your DNA.
 - For example, in cancer treatment, NGS can find out exactly what's wrong with your cancer, so doctors can give you the best medicine for it.
 - Take the case of Emily Whitehead, the first child to receive CAR-T cell therapy for leukemia. By sequencing her DNA, doctors identified specific genetic changes that made her eligible for this revolutionary treatment, which has now saved countless lives.

- **Finding Disease Risks**

- NGS can also tell us if we're likely to get certain diseases.
- Consider the story of Angelina Jolie, who opted for a preventive double mastectomy after NGS revealed she carried a mutation in the BRCA1 gene, significantly increasing her risk of breast and ovarian cancer.
- This proactive approach to healthcare, made possible by NGS, allows individuals to take preventive measures and live healthier lives.

- **Rare Diseases**

- NGS is a lifesaver for people with rare diseases that are hard to diagnose.
- It can find the cause of these diseases quickly, so doctors can start the right treatment early.
- For instance, whole-exome sequencing, a type of NGS, has been instrumental in diagnosing conditions like spinal muscular atrophy and certain types of epilepsy. Early diagnosis means early intervention and better management of these conditions, improving the quality of life for patients and their families.

NGS in Understanding Our Genes

- Now, let's talk about how NGS helps us learn more about our genes and the world around us.

- **The Human Genome Project**

- A big project called the Human Genome Project mapped all our genes, but it took over ten years and a lot of money.
- Now, NGS can do the same thing in just a few days and costs a fraction of what it did. This has opened up new possibilities for research and discovery.

- **Understanding Differences**

- NGS helps scientists understand human diversity at a genetic level.
- By comparing genomes from different populations, researchers can identify genetic variations that contribute to diseases, physical traits, and even behaviors.
- This knowledge is crucial for developing targeted treatments and understanding how our genetics influence our health and well-being.

- **Better Crops**

- Beyond human health, NGS is transforming agriculture by helping scientists develop crops that are more resistant to pests, diseases, and environmental stresses.

- This knowledge is then used to breed crops that can thrive in arid regions, ensuring food security for millions of people.
- This helps farmers grow more food, even in tough conditions.

NGS in Solving Crimes

- Moving on to forensics and criminology, NGS is becoming an invaluable tool in solving crimes and ensuring justice.
 - **Crime Scenes**
 - Imagine a crime scene where investigators find a small bloodstain. Traditional DNA analysis might be able to match this to a suspect, but NGS can provide a much more detailed genetic profile. This can include information about the suspect's ancestry, physical traits, and even their predisposition to certain behaviors.
 - Such detailed genetic information can be crucial in solving complex cases.
 - **Cold Cases**
 - NGS is also helping to solve cold cases that have remained unsolved for decades.
 - For example, in 2018, investigators used NGS to identify the Golden State Killer, a serial killer and rapist who terrorized California in the 1970s and 1980s.
 - By sequencing DNA from crime scene evidence and comparing it to online genealogy databases, they were able to identify a suspect who had eluded capture for over 40 years.
 - **Freeing the Innocent**
 - NGS is also helping free innocent people who were wrongly convicted.
 - The Innocence Project, an organization dedicated to freeing wrongfully convicted individuals, has used NGS to re-examine old evidence and identify the true perpetrators of crimes.
 - This not only brings justice to the innocent but also helps to improve the integrity of our legal system.

NGS for a Better Life

- Ultimately, the widespread adoption of NGS is contributing to a higher quality of life in numerous ways.

- **Public Health**

- NGS helps track diseases and outbreaks.
- During the COVID-19 pandemic, NGS was instrumental in sequencing the virus's genome, which allowed researchers to track mutations and develop vaccines rapidly.
- This capability is essential for responding to future pandemics and protecting public health.

- **Nutrigenomics**

- NGS is also paving the way for personalized nutrition, or nutrigenomics.
- By analyzing an individual's genetic makeup, nutritionists can develop personalized diet plans that optimize health and prevent diseases.
- For example, some people might be genetically predisposed to higher cholesterol levels. With this knowledge, they can adopt a diet that minimizes this risk, leading to better long-term health outcomes.

- **Mental Health**

- In the realm of mental health, NGS is shedding light on the genetic factors that contribute to conditions like depression, anxiety, and schizophrenia.
- By understanding the genetic underpinnings of these conditions, researchers can develop more effective treatments and interventions, helping individuals lead healthier and more fulfilling lives.

The Future of NGS

- Looking to the future, the potential applications of NGS are limitless. As the technology continues to advance, we can expect even greater breakthroughs that will transform our world in ways we can't yet imagine.

- **Editing Genes**

- One exciting frontier is gene editing, particularly with technologies like CRISPR-Cas9. NGS provides the detailed genetic information needed to make precise edits to the genome.
- This has the potential to cure genetic diseases at their source, offering hope to millions of people worldwide.

- **Synthetic Biology**

- In synthetic biology, NGS is enabling the creation of custom organisms designed for specific purposes, such as producing biofuels or cleaning up environmental pollutants.
- By sequencing and editing the genomes of microorganisms, scientists can engineer solutions to some of the world's most pressing challenges.

- **Space Exploration**

- Believe it or not, NGS is even playing a role in space exploration. NASA uses NGS to study how space travel affects the human body at a genetic level.
- This research is crucial for ensuring the health and safety of astronauts on long-duration missions, such as a journey to Mars.

Conclusion

In conclusion, Next-Generation Sequencing is a revolutionary technology that is transforming healthcare, genomics, forensics, and many other fields. Its ability to provide detailed genetic information is leading to breakthroughs that improve our quality of life and open up new possibilities for the future. Whether it's through personalized medicine, understanding our genetic diversity, solving crimes, or advancing public health, NGS is making a profound impact on our world. As we continue to explore and harness its potential, we can look forward to a future where our lives are healthier, safer, and more enriched by the knowledge hidden within our DNA.

As we look ahead, Next-Generation Sequencing is opening up amazing possibilities that will change how we think about health, science, and life itself. Let's embrace this exciting journey and work together to use the power of our DNA to build a healthier and better future for everyone.

Yogesh Agrawal
Chairman

CORPORATE INFORMATION as on 31st March, 2025

Board of Directors:

Mr. Yogesh Agrawal
Mrs. Parul Agrawal
Mr. Ashok Kumar
Mr. Satendra Kumar Goyal

- (Managing Director)
- (Non-Executive Director)
- (Non-Executive and Non-Independent Director)
- (Non-Executive and Independent Director)

Board Committees:

Audit Committee:

Mr. Satendra Kumar Goyal
Mrs. Parul Agrawal
Mr. Ashok Kumar

Statutory Auditors:

M/s Andros & Co.
(Chartered Accountants)
Office: 901, Pearls Omaxe, Plot B-1, NSP, Pitampura,
Delhi-110034
E-mail Id: ca.bhavukgarg@gmail.com

Nomination and Remuneration Committees:

Mr. Satendra Kumar Goyal
Mrs. Parul Agrawal
Mr. Ashok Kumar

Registrar and Share Transfer Agent

Beetal Financial & Computer Services (P) Ltd.
Beetal House, 3rd Floor, 99 Madangir, Behind LSC,
Near Dada, Harsukhdas Mandir, New Delhi-110062

Bankers:

Kotak Mahindra Bank
DCB Bank

Stakeholders Committee:

Mr. Satendra Kumar Goyal
Mrs. Parul Agrawal
Mr. Ashok Kumar

Registered Office:

4 K.M. Stone, Berri Chharra Road Vill.
Kherka, Musalman, P.O. Tandaheri Teh
Bahadu, Jhajjar, Haryana-124507

Risk Management Committee:

Mr. Satendra Kumar Goyal
Mrs. Parul Agrawal
Mr. Ashok Kumar

Corporate Office:

G-74, 2nd Floor, Pushkar Enclave Paschim Vihar,
Delhi- 110063
CIN: L01122HR1994PLC033029
Website: www.genomicvalley.com
Email: genomicvalley@gmail.com

Key Managerial Personnel:

Mr. Yogesh Agrawal- Managing Director/ Chief
Financial Officer
Ms. Anupam Aditya- Company Secretary and
Compliance Officer

Secretarial Auditor:

SBR & Co. LLP
(Practicing Company Secretary)

Internal Auditor:
Mr. Navjyoti Kumar Jha

**Stock Exchange where Company's securities are
listed:**
BSE Limited

GENOMIC VALLEY BIOTECH LIMITED

Regd. Off: 4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana- 124507
CIN: L01122HR1994PLC033029 Tele: +91-9811341542
Email: genomicvalley@gmail.com Visit: <http://www.genomicvalley.com>

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the 31st Annual General Meeting (AGM) of the members of Genomic Valley Biotech Limited will be held on Wednesday, 31st day of December, 2025 at 09.00 A.M. at the Registered Office of the Company at 4 K.M. Stone, Berri Chharra Road Vill. Kherka, Musalman, P.O. Tandaheri Teh Bahadu, Jhajjar, Haryana-124507 to transact the following businesses:

ORDINARY BUSINESS (S):

1. To receive, consider and adopt the Standalone Audited Financial Statements of the Company for the Financial Year ended 31st March 2025, the reports of the Board of Directors and Auditors thereon.
2. To appoint a director in place of Ms. Parul Agrawal (DIN: 01165188), who retires by rotation and being eligible, offers herself for re-appointment.

SPECIAL BUSINESS:

3. **Appointment of Secretarial Auditors of the Company for a term of five years:**

To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 204 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') and the rules made thereunder, Regulation 24A, and other applicable regulations, if any, of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory amendment(s), modification(s) or reenactment(s) thereof, for the time being in force), M/s. SBR & Co. LLP., Practicing Company Secretaries (LLP Reg. No. AAO-9057), be and are hereby appointed as the Secretarial Auditors of the Company for conducting secretarial audit and issuing the secretarial audit report and to do all such actions that may be necessary for a term of five (5) consecutive financial years commencing from April 1, 2025 till March 31, 2030, at such fees, plus applicable taxes and other out-of-pocket expenses, as may be mutually agreed and approved by the Board of Directors of the Company (including its Committee) and the Secretarial Auditors.

RESOLVED FURTHER THAT the Board of Directors of the Company (including its Committee), be and are hereby severally authorized to do all such acts, deeds, matters and things as it may consider necessary, expedient and desirable to give effect to this resolution.”

4. **To appoint and regularization Mr. Yogainder Kumar Gupta (DIN: 03094998) as Independent Director of the Company:**

To consider, and if thought fit, to pass with or without modification, the following resolution as an **Ordinary Resolution:**

“RESOLVED THAT pursuant to provisions of Sections 149(6) 150 and 152, read with Schedule IV and other applicable provisions, if any of the Companies Act, 2013; rules thereof; and other applicable rules and regulations (including any statutory modification(s), amendment(s) or re-enactment thereof for the time being in force) and applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the ‘Listing Regulations’), and pursuant to the terms and conditions recommended by the Nomination & Remuneration Committee, **Mr. Yogainder Kumar Gupta (DIN: 03094998)** who was appointed as an Additional Director in the category of Non-executive Independent Director of the Company by the Board of Directors of the Company and who has submitted a declaration of meeting the criteria for independence as provided in section 149(6) of the Act and who qualifies for being appointed as an Independent Director be and is hereby appointed as Non-Executive Independent Director of the Company, not liable to retire by rotation, to hold office for a term of 5 (Five) consecutive years with effect from May 30, 2025.

RESOLVED FURTHER THAT for the purpose of giving effect to the above resolution, any one of the existing Directors and the Company Secretary of the Company be and are hereby severally authorized to do all such acts, deeds, matters and things and execute all such deeds, documents, instruments and writings as it may in its absolute discretion deem necessary or desirable in relation thereto.”

5. Re-appointment of Mr. Yogesh Agrawal as Chairman and Managing Director of the Company for the period of 5 (Five) years with effect from 07.09.2025:

To consider, and if thought fit, to pass with or without modification, the following resolution as an **Special Resolution**:

“RESOLVED THAT on the recommendation of the Nomination and Remuneration Committee & Board of Directors and pursuant to the provision of Sections 196, 197, 198 and 203 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014, Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Mr. Yogesh Agrawal be and is hereby re-appointed as a Chairman and Managing Director of the Company for a period of 5 (Five) consecutive years with effect from 07.09.2025 on such remuneration of and terms & conditions as detailed below:

1. **Term :** 07th September, 2025 to 06th September, 2030
2. **Nature of Duties:** Mr. Yogesh Agrawal shall devote his whole time and attention to the business of the Company and carry out such duties as may be entrusted to him by the Board from time to time and exercise such powers as may be assigned to him, subject to the superintendence, control and directions of the Board in connection with and in the best interests of the business of the Company.
3. **Salary & Perquisites:** Rs. 2,50,000/- per month (Consolidated).
4. **Minimum Remuneration:** The above remuneration shall also be paid as minimum remuneration to Mr. Yogesh Agrawal in the event of absence or inadequacy of profit in any year during his remaining tenure subject to the ceilings specified under the provision of section 197 and Schedule V of the Companies Act, 2013 having regard to the effective capital of the Company.

The appointment and other service terms will be subject to the relevant provision of the Companies Act, 2013 and as amended from time to time. All other terms and conditions of the existing appointment shall be governed by the agreement and Company rules and policies.

RESOLVED FURTHER THAT the Draft Agreement, incorporating the terms of appointment and remuneration placed at the meeting and initiated by the Chairman thereof for the purposes of identification, be and is hereby approved and any Director or Company Secretary, be and are hereby severally authorized to sign the agreement on behalf of the Company.

RESOLVED FURTHER THAT any Director or Company Secretary, be and are hereby severally authorized to do all such acts, deeds, matters and things in this regard and to file the relevant forms, if any with the Ministry of Corporate Affairs (MCA), Registrar of Companies.”

6. To consider and approve alteration of Object Clause of the Memorandum of Association (“MOA”) of the Company:

To consider, and if thought fit, to pass with or without modification, the following resolution as an **Special Resolution**:

“RESOLVED THAT subject to the provisions of Section 4, 13 and all other applicable provisions, if any, of the Companies Act, 2013 (the “Act”) read with applicable Rules and Regulations made thereunder (including any statutory modification(s) or re-enactment(s)), SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 or any other applicable law(s), regulation(s), guideline(s), and subject to such approvals, permissions and sanctions of appropriate authorities, consent of the members of the Company be and is hereby accorded for the addition of clauses in the object clause of the Memorandum of Association of the Company in the manner set-out below.

Clause III. [A] 15 to 21 be and is hereby inserted after the clause III. [A] 14 as under:

15. To Carry on the business of and to act as Buyer, seller, supplier, importers, exporter, distributors, manufacture and deal in all kinds and varieties of Equipment, technologies, Products used in measurement, analysis, modification, or manipulation of DNA and RNA.

16. To initiate, undertake, carry on, engage in, promote, assist encourage, finance and conduct scientific and technical research, developments, experiments, investigations, inquiries, studies, projects, analysis, examinations, surveys and test of all kinds including, but not limited to those related to medical, Biomedical, Generic and Biotechnology.

17. To carry on the business along with the associates in private or consortium primarily for developing or manufacturing technologies, platforms, reagents, kits, products, services, or solutions that involve the measurement, analysis, modification, or manipulation of an organism's DNA or RNA, Therapeutics, Sequencing-based, Sequencing, Gene Editing, Proactive Healthcare are some of the business models attracting major funding. To carry on the business of detection, structural and functional characterization, measurement, manipulation and modification of an organism's genes and its products by using methods and technology.

18. To carry on business to conduct research, programs, event and activities for the development of applications and its resources based in Biotechnology, Financing/ Grant-in-aid, Genetics education, Genetics trends, Genetics Medical, Genome Project, Industry, Training & Support.

19. The Company shall engage in comprehensive genomics and multi-omics services using advanced high-throughput technologies, including development of proprietary bioinformatics tools for data analysis. It will conduct R&D, design, validate, market, and commercialize diagnostic assays, PCR-based tests, and disease-specific panels, as well as collaborate with medical and public health institutions. The Company may develop vaccines and manufacture reagents, consumables, instruments, and microfluidic/AI-enabled platforms, while providing consultancy for government and private projects.

20. It shall create and operate cloud-based computational systems, databases, and IT infrastructure for healthcare data management in compliance with privacy regulations. The Company will also offer educational and training programs in life sciences, act as a channel partner for national and international biotech firms, and participate in renewable energy and sustainability initiatives linked to biotechnology.

21. To carry on the business of wholesale and commission trade and other allied activities in respect of above objects.

RESOLVED FURTHER THAT any Director or Company Secretary of the Company be and is hereby severally authorized to sign and execute such documents/ papers, file necessary form(s)/ letter(s) with the Registrar of Companies / Ministry of Corporate Affairs, with the Central Government and other concerned authority(ies) and to do all such acts, deeds, matters and things on behalf of the Company as they may deem fit, proper and necessary to give effect to this resolution.”

**For and on behalf of the Board
Genomic Valley Biotech Limited**

Sd/
Anupam Aditya
Company Secretary & Compliance Officer

Date: 08.12.2025

Place: Jhajjar

NOTES:

1. The Explanatory Statement pursuant to Section 102 of the Act setting out the material facts concerning the business under Item Nos. 3 to 6 of the accompanying Notice is annexed hereto as Annexure I. The Board of Directors of the Company considered that the special business under Item No. 3 to 6, being considered unavoidable, be transacted at the 31st AGM of the Company.
2. A member entitled to attend and vote at the meeting is entitled to appoint a proxy, or, where that is allowed, one or more proxies, to attend and vote instead of himself and the proxy need not be a member.
3. A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten per cent of the total share capital of the company carrying voting rights. A member holding more than ten per cent of the total share capital of the company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.
4. The instrument appointing a proxy must be deposited with the company at its registered office not less than 48 hours before the time for holding the meeting.
5. A Proxy Form, Attendance Slip, Ballot Form (in lieu of E-Voting at Annual General Meeting) and Route Map are enclosed with the Notice of Annual General Meeting.
6. Corporate Members intending to send their authorized representatives under Section 113 of the Act are requested to send a duly certified copy of the Board Resolution authorizing their representatives to attend and vote at the meeting, together with duly certified signatures of such representatives.
7. The Company's Registrar and Transfer Agents for its Share Registry Work (Physical and Electronic) is Beetal Financial & Computer Services Private Limited having their office at Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada Harsukh Dass Mandir, New Delhi-110062.
8. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) and Bank details by every participant in securities market. Member(s) holding shares in electronic form are, therefore, requested to submit the PAN to their Depository Participants with whom they are maintaining their demat accounts. Members holding shares in physical form can submit their PAN and Bank details to the RTA.
9. The Register of Members and Share Transfer Books of the Company shall remain closed on the Book Closure Dates, i.e. from December 25, 2025 to December 31, 2025 both days inclusive.
10. Members can avail of the facility of nomination in respect of shares held by them in physical form pursuant to the provisions of section 72 of the Companies Act, 2013 read with Rule 19(1) of the Companies (Share Capital and Debentures) Rules, 2014. Members desiring to avail of this facility may send their nomination in the prescribed Form duly filled in to Beetal Financial & Computer Services Private Limited (RTA) having their office at Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada Harsukh Dass Mandir, New Delhi-110062.
11. Members are requested to:
 - a. Intimate to the Company's Registrar and Transfer Agents, Beetal Financial & Computer Services Private Limited having their office at Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada Harsukh Dass Mandir, New Delhi-110062, changes, if any, in their registered addresses/bank mandates at an early date, in case of shares held in physical form;
 - b. Intimate to the respective Depository Participant, changes, if any, in their registered addresses/ bank mandates at an early date, in case of shares held in electronic/dematerialised form;

- c. Quote their folio numbers/Client ID and DP ID in all correspondence;
- d. Consolidate their holdings into one folio in case they hold shares under multiple folios in the identical order of names.

12. Pursuant to sections 101 and 136 of the Companies Act, 2013, read with the Rules framed thereunder and pursuant to the Circulars issued by the Ministry of Corporate Affairs (MCA) regarding the Green Initiative, the Notice of the 31st Annual General Meeting (AGM) and the Annual Report for the year 2024-25, etc., would be sent in electronic mode to such of the Members of the Company whose e-mail addresses are available with the Company/ Depository Participant and who have not opted to receive the same in physical form.

13. For Members who have not registered their e-mail addresses, physical copies of the Annual Report for the year 2024-25 and the Notice of the 31st AGM would be sent in the permitted mode.

14. Members are requested to support the Green Initiative by registering / updating their e-mail addresses, with the Depository Participant (in case of Shares held in dematerialised form) or with Beetal Financial & Computer Services Private Limited having their office at Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada HarsukhDass Mandir, New Delhi-110062. **(In case of Shares held in physical form)**

15. Members may also note that the Notice of the 31st Annual General Meeting and the Annual Report for financial year 2024-25 will also be available on the Company's website at [www.http://genomicvalley.com/investorrelationpage.htm](http://genomicvalley.com/investorrelationpage.htm) and also on the website of the RTA, Beetal Financial & Computer Services Private Limited at <http://beetalfinancial.com>. Even after registering for e-communication, Members are entitled to receive such communication in physical form, upon making a request to the Company for the same. For any communication, the shareholders may also send requests to the Company's Email ID : genomicvalley@gmail.com.

16. Relevant documents referred to in the accompanying Notice shall be open for inspection at the Registered Office of the Company during normal business hours on all working days except Sunday from 10.00 A.M. to 6.00 P.M., up to and including the date of the Annual General Meeting of the Company.

17. The Register of Directors and Key Managerial Personnel and their Shareholding maintained under Section 170 of the Companies Act, 2013, the Register of Contracts or arrangements in which Directors are interested under Section 189 of Companies Act, 2013 will be available for inspection at the Annual General Meeting.

18. Members/Proxies/Representatives are requested to bring their Attendance Slip along with their copy of Annual Report to the Meeting.

Only Bonafide members of the Company whose names appear on the Register of Members/Proxy holders, in possession of valid attendance slips duly filled and signed will be permitted to attend the meeting. The Company reserves its right to take all steps as may be deemed necessary to restrict non-members from attending the meeting.

19. Members are requested to bring their copies of Annual Report to the Meeting. In order to enable us to register your attendance at the venue of the Annual General Meeting, members are requested to please bring their folio number/ demat account number/DP ID-Client ID to enable us to provide a duly filled attendance slip for your signature and participation at the meeting.

20. In case of joint holders attending the meeting, only such joint holder who is higher in the order of names will be entitled to vote.

21. E-voting:

In compliance with the provisions of the Sections 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014, the Company is pleased to members with a facility to exercise their right to vote the 31st Annual General Meeting by electronic means and the business may be transacted through Electronic Voting (e-voting) services provided by the Central Depository Services Limited (CDSL).

The Company has appointed Mr. Rohit Batham, Partner of SBR & Co. LLP, Company Secretaries as the Scrutinizer for conducting the e-voting process in a fair and transparent manner. E-voting is optional. The E-voting rights of the shareholders/beneficiary owners shall be reckoned on the equity shares held by them as on 24th December, 2025 being the Cut-off date for the purpose. Shareholders of the Company holding shares either in physical or in dematerialized form, as on the Cut-off date, may cast their vote electronically.

In order to enable its members, who do not have access to e-voting facility, to send their assent or dissent in writing in respect of the resolutions as set out in this Notice, a ballot paper is annexed. A member desiring to exercise vote by ballot paper shall complete the enclosed ballot paper with assent (for) or dissent (against) and send it to Registered office of the Company so as to reach us on or before 30th December, 2025 by 5.00 P.M. Any ballot paper received after the said date and time shall be treated as if the reply from the Members has not been received. Kindly note that member can opt only one mode of voting i.e., either by ballot paper or through e-voting. If members are opting for e-voting then do not vote by ballot paper or vice versa. However, in case of Members casting their vote both by ballot paper and e-voting, then voting done through e-voting shall prevail and voting done by Physical Ballot will be treated as invalid.

22. Instruction for E-Voting:

21.1 **Step 1:** Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

Step 2: Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

a. The e-voting period begins on December 28, 2025 at 9.00 a.m. and ends on December 30, 2025 at 5.00 p.m. During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of December 24, 2025, may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.

b. Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.

c. Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

d. **Step 1:** In case of individual shareholders holding shares in demat mode: Access through Depositories CDSL/NSDL e-Voting system.

In terms of **SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020** on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to abovesaid SEBI Circular, Login method for **e-Voting for Individual shareholders holding securities in Demat mode CDSL/NSDL** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL Depository	<ol style="list-style-type: none">1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit cdsl website www.cdslindia.com and click on login icon & My Easi New (Token) Tab.2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.3) If the user is not registered for Easi/Easiest, option to register is available at cdsl website www.cdslindia.com and click on login & My Easi New (Token) Tab and then click on registration option.4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.

<p>Individual Shareholders holding securities in demat mode with NSDL Depository</p>	<ol style="list-style-type: none"> 1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period. 2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS "Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period. 4) For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
<p>Individual Shareholders (holding securities in demat mode) login through their Depository Participants</p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.</p>

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at : 022 - 4886 7000 and 022 - 2499 7000

Step 2: Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode

(i) Login method for e-Voting and joining virtual meetings for Physical shareholders and shareholders other than individual holding in Demat form.

1. The shareholders should log on to the e-voting website www.evotingindia.com.
2. Click on "Shareholders" module.
3. Now enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
4. Next enter the Image Verification as displayed and Click on Login.
5. If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.
6. If you are a first-time user follow the steps given below:

	For Physical shareholders and other the individual shareholders holding shares in Demat.
PAN	<p>Enter your 10-digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders)</p> <ul style="list-style-type: none"> Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth	<p>Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login.</p> <ul style="list-style-type: none"> If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.

- (ii) After entering these details appropriately, click on “SUBMIT” tab.
- (iii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (iv) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (v) Click on the EVSN for the relevant <Company Name> on which you choose to vote.
- (vi) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (vii) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (viii) After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (ix) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (x) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xi) Shareholders can also cast their vote using CDSL’s mobile app “m-Voting”. The m-Voting app can be downloaded from respective Store. Please follow the instructions as prompted by the mobile app while Remote Voting on your mobile.
- (xii) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xiii) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.

(xiv) Additional Facility for Non - Individual Shareholders and Custodians - For Remote Voting only.

- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
- A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; cs.gvbl@gmail.com, if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self- attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to Company/RTA email id.
2. For Demat shareholders - Please update your email id & mobile no. with your respective Depository Participant (DP)
3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call toll free no. 1800 21 09911.

- 22 Any person who acquires shares of the Company and become Member of the Company after dispatch of the Notice and holding shares as on the cut-off date i.e. Wednesday 24th December, 2025 may follow the same instructions as mentioned above for e-Voting.
- 23 In case a member receives physical copy of the Annual General Meeting Notice by post (for members whose email Ids are not registered with the Company/Depository Participant(s)):
User ID and initial password are provided overleaf.
Please follow all steps from Note 22.1 above to cast your vote.
- 24 Once the vote on a resolution is cast by a Member, the Member shall not be allowed to change it subsequently or cast the vote again.
- 25 In case of any queries, you may refer to the Frequently Asked Questions (FAQs) for Members and e- voting user manual for Members available at the 'downloads' section of www.evoting.india.com.
- 26 The facility for ballot / polling paper shall be made available at the Annual General Meeting (AGM) and the members attending AGM who have not cast their vote by e-voting/ ballot paper shall be able to vote at the AGM through ballot / polling paper.
- 27 The members who have cast their vote by e-voting may also attend AGM but shall not be entitled to cast their vote again.
- 28 The voting rights of the Members for e-voting shall be in proportion to the paid-up value of their shares in the equity share capital of the Company as on the cut-off date i.e. 24th December, 2025.
- 29 Persons, whose names are recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date i.e. 24th December, 2025 only shall be entitled to avail the facility of e-voting / physical voting.
- 30 The poll process shall be conducted and a report thereon shall be prepared in accordance with Section 109 of the Companies Act, 2013 read with the relevant rules made there under. In such an event, votes cast under Poll taken together with the votes cast through remote e- voting shall be counted for the purpose of passing of resolution(s).

- 31 The Scrutinizer shall immediately after the conclusion of voting at the AGM, count the votes cast at the AGM and thereafter unblock the votes cast through remote e-voting in the presence of at least two (2) witnesses not in the employment of the Company. The Scrutinizer shall submit a consolidated Scrutinizers Report of the total votes cast in favour of or against, if any, not later than two (2) days after the conclusion of the AGM to the Chairman of the Company.
- 32 The Chairman or any other director authorized by him, shall declare the result if the voting forthwith.
- 33 The results on resolutions shall be declared forthwith after getting the report of Scrutinizer and the resolutions will be deemed to be passed on the date of Annual General Meeting subject to receipt of the requisite number of votes in favour of the resolutions.
- 34 The Results declared along with the Consolidated Scrutinizer's Report(s) will be available on the website of the Company (www.genomicvalley.com) and on website of CDSL. The results shall simultaneously be communicated to Stock Exchanges.
- 35 Members desiring any information relating to the accounts are requested to write to the Company well in advance so as to enable the management to keep the information ready.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

Item No. 3:

As per the amendment in the Securities And Exchange Board of India (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024, M/S SBR & Co. LLP., Practicing company secretaries, were appointed as the secretarial auditors of the company for the period of five years from the conclusion of this 31st AGM till the conclusion of the 36th AGM of the Company.

On the recommendation of the Board of Directors, recommended for the approval of the members, the appointment of M/S SBR & Co. LLP, Practicing company secretaries of the Company for a period of five years from the conclusion of this 31st AGM till the conclusion of the 36th AGM of the Company, at a remuneration mutually decided by the Board of Directors and Auditor and reimbursement of out of pocket expenses to conduct the secretarial Audit. The remuneration for the subsequent year(s) of their term shall be determined based on the recommendation of the Board and as mutually agreed between the Board of Directors of the Company and the Secretarial Auditors.

M/S SBR & Co. LLP., Practicing company secretaries is a firm of Company secretaries in Ghaziabad, India. M/S SBR & Co. LLP., provides services in the fields of secretarial services and consulting keeping in mind the regulatory and commercial environment within which the Firm's clients operate. The Company has obtained a certificate from the secretarial auditors of the Company that they meet the criteria of independence, eligibility and qualification as prescribed in Section 204 of the Act. As required under the SEBI Listing Regulations, M/S SBR & Co. LLP, has confirmed that they hold a valid certificate issued by the Peer Review Board of ICSI.

None of the directors and key managerial personnel or their relatives are interested financially or otherwise in the resolution as set out in item no. 3 of this notice.

The Board recommends the resolution set out at Item No. 3 of the Notice for approval by the Members by way of an Ordinary Resolution.

Item Nos. 2, 4 & 5

Details of Director seeking Appointment / Re-appointment pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Particulars	Mr. Yogesh Agrawal	Ms. Parul Agrawal	Mr. Yogainder Kumar Gupta
Directors Identification Number (DIN)	01165288	01165188	03094998
Date of Birth (age)	16-05-1963	01-11-1970	08-04-1959
Qualification	Chartered Accountant	Graduated	B.Com
Expertise in Specific area/ Brief Resume	<p>He is having wide experience in business activities right from the beginning of his career. He successfully operated several Private Limited and Public Limited Companies during his 38 years of exposure.</p> <p>Under his able and experienced guidance and direction M/s Genomic Valley Biotech Limited is progressing well in leaps and bound.</p> <p>He is one of the promoters of the Company.</p>	<p>Mrs. Parul Agrawal is Graduated in Economics (BA Hons) and having Experience of 31+ years in Management.</p>	<p>Yogainder Kumar Gupta is having Experience in the field of Finance and real estate of 44 years. He has completed his graduate with Degree of Bachelors of Commerce (B.Com).</p> <p>He started his career at a tender age and has gained exposure to many fields in the past few years enhancing his core skills and expertise. He carries an intellectual personality and has relevant expertise.</p>
Date of first appointment on the Board of the Company	07/09/2025	14/02/2024	30/05/2025
Shareholding in Genomic Valley Biotech Limited as on 31 st March 2025	1427000 Eq. shares	NIL	NIL
List of Directorship held in other companies	<p>1. Genomic Valley Bharat Private Limited</p> <p>2. Eyoge Media Entertainment Private Limited</p> <p>3. Kannu Aditya (India) Limited</p> <p>4. Rishikesh School of Yoga Foundation</p> <p>5. UCC Entertainment Media Private Limited</p>	<p>1. Rishikesh School of Yoga Foundation</p> <p>2. Genomic Valley Bharat Private Limited</p> <p>3. Eyoge Media Entertainment Private Limited</p>	NIL
Membership/Chairmanship Committees	NIL	<p>Members in following committee:-</p> <p>1. Audit Committee</p> <p>2. Nomination and Remuneration Committee</p> <p>3. Stakeholder Relationship Committee</p> <p>4. Risk Management Committee</p>	NIL
Relationship with other directors interse	Ms. Parul Agrawal, Director and wife of Mr. Yogesh Agrawal	Wife of Mr. Yogesh Agrawal, Chairman and managing director of the company.	NIL
Terms & Conditions of re-appointment including remuneration payable	Re-appointment in terms of Section 152(6) of the Companies Act, 2013.	Subject to approval of the Shareholders of the Company, by means of a special resolution and Liable to retire by rotation [In accordance with the Companies Act, 2013.	Subject to approval of the Shareholders of the Company, by means of a special resolution and not liable to retire by rotation [In accordance with the Companies Act, 2013.
Number of Meetings of Board attended during the year	6	6	NIL
Details of remuneration sought to be paid and last drawn	Rs. 2,50,000/-	NIL	NIL

Skills and capabilities required for the role and the manner in which the proposed person meets such requirements	He has over 38 years of business experience and has successfully managed several Private and Public Limited Companies. Under his guidance, M/s Genomic Valley Biotech Limited has shown significant progress.	She has Skills, capabilities and Area of Expertise in finance, diversity, Global Business, Leadership, Technology, Mergers & Amalgamations, Board Service & Governance and Sales & Marketing.	He began his career at a young age and has gained valuable exposure across various fields, strengthening his core skills and expertise. He carries an intellectual personality with relevant professional competence.
---	---	---	---

Item No. 6

Alteration of the Object Clause of the Memorandum of Association of the Company.

Your Board has to consider from time to time proposals for diversification into areas which would be profitable for the Company as part of diversification Plans. For this purpose, the Objects Clause of the Memorandum of Association of the Company ('MOA'), which is presently restricted in scope, is required to be comprehensive so as to cover a wide range of activities to enable your Company to consider embarking upon new projects and activities.

The alteration in the Objects Clause of the MOA as set out in the Resolution is to facilitate diversification. This will enable the Company to enlarge its area of operations and carry on its business economically and efficiently and the proposed activities can be, under the existing circumstances, conveniently and advantageously combined with the present activities of the Company.

The "Main Object" clause of the MOA of the Company is being amended by inserting new sub-clause 15 to 21 after the existing said sub-clause 14.

None of the Directors, Key Managerial Person(s) of the Company including their relatives are, in any way, concerned or deemed to be interested in the proposed resolution.

The Board recommends the Special Resolution set forth in **Item No. 6** of the Notice for approval of the Members.

GENOMIC VALLEY BIOTECH LIMITED

Regd. Off: 4 KM Stone, Berri Chharra Road, P.O. Tandaheri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana- 124507

CIN:L01122HR1994PLC033029 Tele :- +91-9811341542

Email:genomicvalley@gmail.com Visit:<http://www.genomicvalley.com>

Form No. MGT-11 PROXY FORM

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN	L01122HR1994PLC033030
Name of the company	Genomic Valley Biotech Limited
Registered office	4 K.M. Stone, Berri Chharra Road Vill. Kherka, Musalman, P.O. Tandaheri Teh Bahadu, Jhajjar, Haryana-124507

Name of the Shareholder	
Registered address	
E-mail ID	
Folio No./Client ID	
DP ID	

I/We, being the member (s) of Genomic Valley Biotech Limited holding.....Equity Shares, hereby appoint:

1.	Name	
	Address	
	E-mail Id	
	Signature	

or failing him

2.	Name	
	Address	
	E-mail Id	
	Signature	

or failing him

3.	Name	
	Address	
	E-mail Id	
	Signature	

As my/ our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 31st Annual General Meeting of the Company to be held on Wednesday, 31st day of December, 2025 at 09.00 A.M. at the Registered office of the Company at 4 K.M. Stone, Berri Chharra Road Vill. Kherka, Musalman, P.O. Tandaheri Teh Bahadu, Jhajjar, Haryana- 124507and at any adjournment thereof in respect of such resolutions as are indicated below:

ORDINARY BUSINESS(ES)

1. To receive, consider and adopt the Standalone Audited Financial Statements of the Company for the Financial Year ended 31st March 2025, the reports of the Board of Directors and Auditors thereon.
2. To appoint a director in place of Ms. Parul Agarwal (DIN: 01165188), who retires by rotation and being eligible, offers herself for re-appointment.

SPECIAL BUSINESS(ES)

3. To consider and re-appoint M/s SBR & Co. LLP (LLP Reg. No. AAO-9057) as Secretarial Auditors of the Company and to fix their remuneration.
4. To Appoint and regularization Mr. Yogainder Kumar Gupta (DIN: 03094998) as Independent Director of the Company.
5. Re-appointment of Mr. Yogesh Agrawal as Chairman and Managing Director of the Company for the period of 5(Five) years with effect from 07.09.2025.
6. To consider and approve alteration of Object Clause of the Memorandum of Association (“MOA”) of the Company.

Signed this..... day of..... 2025

Affix
Revenue
Stamp of
Re 1

Signature of shareholder:

Signature of Proxy holder(s):

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI, TEHSIL- BAHADURGARH, DISTT-JHAIJAR, HARYANA-124507
CIN:L01122HR1994PLC033029 Tele:- +91-9811341542
Email :genomicvalley@gmail.com Visit :<http://www.genomicvalley.com>

ATTENDANCE SLIP

PLEASE BRING THIS ATTENDANCE SLIP AND HANDOVER AT THE ENTRANCE OF 31ST ANNUAL GENERAL MEETING VENUE AT 4 K.M. STONE, BERRI CHHARRA ROAD P.O. TANDAHERI, TEH. BAHADURGARH, DIST. JHAIJAR, HARYANA-124507.

Name & Address of the Shareholder

.....
.....
.....
.....
.....
.....
.....

SEQUENCE NO. :
FOLIO NO. :
DP ID :
CLIENT ID :
.....

I hereby record my presence at the 31st Annual General Meeting being held at 4 K.M. Stone, Berri Chharr Road Vill. Kherka, Musalman, P.O. Tandaheri Teh Bahadurgarh, Jhajjar, Haryana, India, 124507 on Wednesday, the 31st day of December, 2025 at 09:00 A.M.

Signature of Member or Proxy

No. of Shares held

Notes:

1. A member or his duly appointed Proxy wishing to attend the meeting must complete this Attendance Slip and hand it over at the entrance.
2. Name of the Proxy in Block letters(in case the Proxy attends the meeting)
1. Those who hold shares in Demat form to quote their Demat Account No. and Depository Participant (D.P.) ID. No.
2. Shareholders/proxy holders desiring to attend the meeting may bring his/her copy of Annual Report for reference at meeting.

Electronic Voting Particulars

Electronic Voting Sequence No. (EVSN)	User ID	Sequence Number

Note: Please read the instructions printed in the Notice dated 08th December, 2025 of the 31st Annual General Meeting. The voting period starts from Sunday 28th December, 2025 at 9:00 a.m. and ends on Tuesday, 30th December, 2025 at 05:00 p.m. The Voting module shall be disabled by CDSL for voting thereafter.

GENOMIC VALLEY BIOTECH LIMITED

**Regd. Off: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI, TEHSIL-BAHADURGARH, DISTT-JHAJJAR,
HARYANA-124507**

CIN: L01122HR1994PLC033029 Tele :- +91-9811341542

Email :genomicvalley@gmail.com Visit :<http://www.genomicvalley.com>

BALLOT FORM (In lieu of E-Voting at the Annual General Meeting)

1	Name of the Sole/First Member	
2	Name(s) of the Joint Member(s), if any	
3	Registered Folio No./DP ID /Client ID	
4	Number of shares held	

I/we hereby exercise my/our vote in respect of the resolution(s) to be passed through e-voting/ for the business stated in the AGM Notice dated 31st December, 2025 of the Company by convening my/our assent or dissent to the said Resolution(s) by packing the tick (v) mark at the approximate box below:

Item No.	Description	No. of shares held by	I assent to the	I dissent from
	Ordinary Business(es)			
1	To receive, consider and adopt the Standalone Audited Financial Statements of the Company for the Financial Year ended 31 st March 2025, the reports of the Board of Directors and Auditors thereon.			
2	To appoint a director in place of Ms. Parul Agarwal (DIN: 01165188), who retires by rotation and being eligible, offers himself for re-appointment.			
	Special Business(es)			
3	To Consider and Re-appoint M/s SBR & Co. LLP. (LLP Reg. No. AAO-9057) as Secretarial Auditors of the Company and to fix their remuneration.			
4	To appoint and regularization Mr. Yoginder Kumar Gupta (DIN: 03094998) as Independent Director of the Company			
5	Reappointment of Mr. Yogesh Agrawal as Chairman and Managing Director of the Company for the period of 5 (Five) years with effect from 07.09.2025.			
6	To consider and approve alteration of Object Clause of the Memorandum of Association ("MOA") of the Company.			

Place:

Date:

Signature of Member

NOTE: Last date for receipt of forms by the Company is 30th December, 2025.

GENOMIC VALLEY BIOTECH LIMITED

**Regd. Off: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI, TEHSIL- BAHADURGARH,
DISTT-JHAJJAR, HARYANA-124507**

CIN:L01122HR1994PLC033029 Tele :- +91-9811341542

Email :genomicvalley@gmail.com Visit :<http://www.genomicvalley.com>

Form No. SH-13

Nomination Form

[Pursuant to Section 72 of the Companies Act, 2013 and rule 19(1) of the Companies (Share Capital and Debentures) Rules 2014]

Name of the Company: Genomic Valley Biotech Limited

Registered Address of the Company: 4 K.M. STONE, BERRI CHHARRA ROAD VILL. KHERKA,
MUSALMAN, P.O. TANDAHERI TEH BAHADU, JHAJJAR,
HARYANA- 124507

I/We _____ the holder(s) of the securities, particulars of which are given hereunder, wish to make nomination and do hereby nominate the following persons in whom shall vest, all the rights in respect of such securities in the event of my/our death.

(1) PARTICULARS OF THE SECURITIES (in respect of which nomination is being made):

Nature of	Folio No.	No. of securities	Certificate	Distinctive No.

(2) PARTICULARS OF NOMINEE'S–

- (a) Name:
- (b) Date of Birth:
- (c) Father's/Mother's/Spouse's name:
- (d) Occupation:
- (e) Nationality:
- (f) Address:
- (g) E-mail Id. & Telephone No.:
- (h) Relationship with the security holder(s):

(3) IN CASE NOMINEE IS A MINOR–

- (a) Date of birth:
- (b) Date of attaining majority:
- (c) Name of guardian:
- (d) Address of guardian:

(4) PARTICULARS OF NOMINEE IN CASE MINOR NOMINEE DIES BEFORE ATTAINING AGE OF MAJORITY–

- (a) Name:
- (b) Date of Birth:
- (c) Father's/Mother's/Spouse's name:
- (d) Occupation:
- (e) Nationality:
- (f) Address:

- (g) Email Id. & Telephone No.:
- (h) Relationship with the security holder(s):
- (i) Relationship with the minor nominee:


Name(s) and Address of Security holder(s)

Signature(s)

Name and Address of Witness

Signature (s)

Route Map



The Symbol is indicating Registered Office of the Company (4 K.M. Stone, Berri Chharra Road Vill. Kherka, Musalman, P.O. Tandaheri Teh Bahadu, Jhajjar, Haryana, India, 124507) which is nearby Landmark as PDM College of Engineering.



Board Report

To
The Members

The Directors of the Company take pleasure in presenting the 31st Annual Report on the business and operations of the Company along with the Audited Financial Statements (Standalone) for the financial year ended 31st March, 2025.

FINANCIAL RESULT

The company performance for the financial year ended on March 31, 2025 is summarized below:

Particulars	2024-25	2023-24 (In Rs.)
Revenue from Operations	84,39,394	16,50,750
Other Income	44,660	15,003
Total Revenue	84,84,054	16,65,753
Total Expenses	40,69,678	15,14,273
Profit before Exceptional Items and Tax	44,14,376	1,51,480
Exceptional Item	-	-
Profit before Tax	44,14,376	1,51,480
Tax Expenses	8,53,444	-339
Profit After Tax for the year	35,60,932	1,51,818
EPS	1.17	0.05

STATE OF COMPANY AFFAIRS AND FUTURE OUTLOOK:

During the aforesaid period, the revenues from operations stood at Rs 84,39,394/- Further, the Company had incurred total expenses of Rs. 40,69,678/-.

- **THE CHANGE IN NATURE OF BUSINESS, IF ANY**

There was no change in the nature of business of the Company during the year we added human genomics services.

- **PRESENT AND FUTURE PROSPECTIVES:**

PRESENT ACTIVITIES

1. Providing consultancy in:
 - a. High-Tech Cultivation through Environment Controlled Poly Houses, NFT & DFT etc.
 - b. Organic Farming --- Open Field Cultivation using Bio-Fertilizer.
2. Trading in agricultural and horticultural products



3. Providing Next Generation Sequencing (NGS) services.
4. Genetic Counselling for Preventive and Targeted Therapeutics.
5. We have signed an agreement with Artemis Hospital Gurgaon to leverage their state-of-the-art wet lab for Next-Generation Sequencing (NGS) analysis, enhancing precision in genomic research and diagnostics.
6. Celebrating our key milestones achieved during the year.

This year has been pivotal for Genomic Valley, as we accomplished several major milestones that highlight our dedication to innovation, collaboration, and excellence in genomics:

- **Website Development and Optimization:**

We launched and optimized a dynamic website to serve as a hub for our services and values. This platform enhances customer engagement, provides seamless access to information, and reflects our commitment to cutting-edge innovation.

- **Expansion of Services and Offerings:**

We broadened our service portfolio to include advanced genomic pipelines like Whole Genome Sequencing, Exome Sequencing, Gut Microbiome Analysis, and Targeted Sequencing Panels. These expansions demonstrate our focus on meeting diverse healthcare and research needs.

- **Projects on Chronic Kidney Disease and Ayurveda Hair Follicle Growth Study:**

We initiated two groundbreaking projects: one exploring the genetic basis of Chronic Kidney Disease (CKD) and another combining genomics with Ayurveda in a Hair Follicle Growth Study. These initiatives underline our ability to merge traditional and modern approaches to tackle healthcare challenges.

- **Database Creation and Market Research:**

By building a comprehensive database and conducting in-depth market research, we have enhanced our understanding of healthcare trends, enabling us to deliver solutions that meet the needs of patients and clinicians effectively.

- **Events, Workshops, and Webinars:**

Organizing events, workshops, and webinars with academic institutions, healthcare providers, and industry leaders. These engagements have strengthened our expertise, visibility, and partnerships.

- **Chatbot and Domain Setup:**

To enhance customer interaction, we developed and deployed a chatbot along with domain setup. These tools provide instant support and improve the user experience on our platform.

- **Email Marketing, Invoicing, and CRM Setup:**

We integrated email marketing, invoicing, and customer relationship management (CRM) tools to streamline communication and operations, ensuring efficient processes and improved client engagement.



- **Razorpay Setup, Payment Integration, and Server Setup:**

With Razorpay integration and server setup, we have built a secure and efficient payment system on our website, ensuring seamless transactions and reinforcing trust with our clients.

FUTURE ACTIVITIES

1. Pharmaceutical Genomics and Biomanufacturing:

- To pioneer the integration of genomics in pharmaceutical development for targeted therapies.
- To establish scalable and efficient biomanufacturing processes for producing biologics and gene therapies.
- To contribute to global drug discovery efforts through genomic insights and AI-driven methodologies.

2. Research and Development:

- To lead innovations in all areas of human genomics, with a specific focus on identifying novel genetic biomarkers and therapeutic targets in oncology.
- To integrate Next-Generation Sequencing (NGS) with AI for rapid, precise, and cost-effective oncology diagnostics.
- To establish strategic collaborations with academic and industry leaders for translational cancer research.

3. Radiogenomic Innovations in Cancer Diagnosis and Treatment:

- Lead advancements in radiogenomics by integrating imaging and genomic data to enhance cancer diagnosis and personalized treatment strategies.
- Identify novel genetic biomarkers and therapeutic targets through radiogenomic analysis, with a specific focus on improving precision in oncology.
- Develop machine learning-driven models to correlate radiological features with genetic mutations, facilitating early detection and accurate classification of cancer subtypes.
- Create robust, user-friendly applications for clinical use, enabling healthcare providers to access predictive insights and optimize patient care.

BIOTECHNOLOGY INDUSTRY GROWTH

The growth of Biotechnology industry as per Transparency Market Research is estimated to observe substantial growth during 2010 and 2018 as investments from around the world are anticipated to rise, especially from emerging economical regions of the world. The report states that the global market for biotechnology, studied according to its application areas, shall grow at an average annual growth rate of CAGR 11.6% from 2012 to 2018 and reach a value worth USD 414.5 billion by the end of 2018. This market was valued approximately USD 216.5 billion in 2011. The market of bio agriculture, combined with that of bio seeds, is projected to reach a value worth USD 27.46 billion by 2019. The field of biopharmaceuticals dominated the global biotechnology market and accounted for 60% shares of it in the year 2011. Many biotechnological industries flourished by the technological advancements leading to new discoveries and rising demands from the pharmaceutical and agricultural sectors.

PUBLIC DEPOSIT

During the year under review, the company has not accepted any deposit under Section 73 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014.

SHARE CAPITAL

The Authorized Share Capital of the Company as on March 31, 2025, stood at Rs.9,00,00,000/- divided into 90,00,000 equity shares of Rs. 10/- each. The Paid-up Equity Share Capital as of March 31, 2025, stood at Rs.3,05,45,000/-divided into Rs. 30,54,500 equity shares of Rs.10/-each fully paid.



Share Capital	March 31, 2025	March 31, 2024
Authorized Capital	9,00,00,000	9,00,00,000
Issue Capital	8,15,00,000	8,15,00,000
Subscribed Capital	7,69,73,000	7,69,73,000
Less: Share Forfeiture	4,64,28,000	4,64,28,000
Paid Up Capital	3,05,45,000	3,05,45,000

LOANS, GUARANTEES & INVESTMENTS

Details of Loans, Guarantees or Investments covered under the provisions of Section 186 of the Companies Act, 2013 ("the Act") are given in the notes to the financial statements.

BUSINESS RESPONSIBILITY REPORT

As per Regulation 34(2)(f) of the SEBI (LODR) Regulations, 2015, top five hundred (500) listed entities based on market capitalization shall contain the Business Responsibility Report in their Annual Report. As the Company does not fall under top 500 listed Companies based on market capitalization, therefore, this regulation is not applicable to the Company

DIVIDEND

Although there is profit in the Company during the year but need to conserve resources for the expansion of the business of your Company, Board expresses its inability to declare any dividend for the financial year 2024-25.

RESERVES

The company is having less profit in financial year 2024-25. Therefore, no amount was transferred into reserve account.

MATERIAL CHANGES AND COMMITMENTS

There are no material changes and commitments effecting the financial position of the company which have occurred during the financial year 2024-25 of the company to which the financial statement relates to the date of this report.

BOARD OF DIRECTORS AND OTHER KEY MANAGERIAL PERSONNEL

The Company is managed and controlled by a Board comprising an optimum blend of Executives and Non-Executive Professional Directors. As on March 31, 2025; the Board of Directors consists of Five (4) Directors including One (1) Managing Director cum Executive Director, One (1) Non-executive Independent Director and Two (2) Non- Executive and Non-Independent Director including one Woman Director. All the Directors possess the requisite qualifications and experience in general Corporate Management, Finance, banking and other allied fields which enable them to contribute effectively to the Company in their capacity as Directors of the Company.

Following are the details of Directors and Key Managerial Personnel (KMP) of the Company along with changes as placed during the Financial Year 2024-2025.

Sr. No.	Name of Directors	Designation	DIN	Date of Appointment	Date of Resignation
1.	Mr. Yogesh Agrawal	Managing Director	01165288	07/09/2015	-
2.	Mr. Praveen Kumar	Non-Executive	-	09165954	30/06/2023
					28/08/2024



	Mishra*	Independent Director			
3.	Mrs. Parul Agrawal	Non Executive - Non Independent Director	01165188	14/02/2024	-
4.	Mr. Ashok Kumar	Additional Executive (Non Executive - Non Independent Director)	07647876	14/11/2023	-
5.	Mr. Yogesh Agrawal	Chief financial officer	-	30/06/2023	-
6.	Mrs. Anupam Aditya	Company Secretary & Compliance Officer	-	31/03/2023	-
7.	Mr. Ashok Kumar Khattar	Additional Non-Executive and Independent Director	00516458	06/12/2024	08/01/2025
8.	Mr. Satendra Kumar Goyal	Non-Executive and Independent Director	08767544	09/05/2024	-
9.	Mr. Yogainder Kumar Gupta*	Non-Executive and Independent Director	03094998	30/05/2025	-

*Appointed as Additional Non-Executive Independent Director after closure of financial year.

Change in Board Composition:

Mr. Ashok Kumar Khattar was appointed as an Additional Non-Executive (Independent) Director on the Board with effect from 06th December, 2024 and resigned as Non-Executive (Independent) Director w.e.f. 08th January, 2025.

Mr. Praveen Kumar Mishra was resigned as Non-Executive (Independent) Director with effect from 28th August, 2024.

NUMBER OF MEETINGS OF THE BOARD

The Board meets at regular intervals to discuss and decide on Company / business policy and strategy apart from other Board business. The Board / Committee Meetings are pre-scheduled and a tentative annual calendar of the Board and Committee Meetings is circulated to the Directors well in advance to facilitate them to plan their schedule and to ensure meaningful participation in the meetings. However, in case of a special and urgent business need, the Board's approval is taken by passing resolutions by circulation, as permitted by law, which is noted and confirmed in the subsequent Board meeting.

The notice of Board meeting is given well in advance to all the Directors. Usually, meetings of the Board are held at registered office. The Agenda of the Board / Committee meetings is set by the Company Secretary in consultation with the Chairman of the Company. The Agenda is circulated a week prior to the date of the meeting.

The Agenda for the Board and Committee meetings includes detailed notes on the items to be discussed at the meeting to enable the Directors to take an informed decision.

During the Financial Year 2024-25, Six Board meetings were held on:

1. 09th May, 2024
2. 29th July, 2024
3. 5th September, 2024
4. 07th October, 2024
5. 06th December, 2024
6. 14th February, 2025

The maximum interval between any two meetings was well within the maximum allowed gap of 120 days.



The details of attendance of each director at the Board meetings are as given below:

Name of Director	Date of Original Appointment	Date of Cessation	Number of Board Meetings eligible to attend	Number of Board Meetings attended
Mr. Yogesh Agrawal	07/09/2015	-	6	6
Mr. Praveen Kumar Mishra	30/06/2023	28/08/2024	2	2
Mrs. Parul Agrawal	14/02/2024	-	6	6
Mr. Ashok Kumar	14/11/2023	-	6	0
Mr. Satendra Kumar Goyal	09/05/2024	-	5	5

COMMITTEES AND THEIR MEETINGS

➤ Audit Committee

The Company has an Audit Committee of Directors in compliance with provisions of the Companies Act, 2013 and Regulation 18 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Committee comprises of:

- Mr. Satendra Kumar Goyal (Non-Executive and Independent Director, Chairman)*.
- Mrs. Parul Agrawal (Non- Executive and Non-Independent Director).
- Mr. Ashok Kumar (Non- Executive and Non- Independent Director).

* Mr. Satendra Kumar Goyal was appointed as Independent Director on 09th May, 2024 and Mr Praveen Kumar Mishra resigned from the Independent Director on 28th August, 2024.

The terms of reference of the Audit Committee inter alia include overseeing the financial reporting process, reviewing the financial statements and recommending the appointment of Auditors. All the recommendations made by Audit Committee were accepted.

During the year, Four (09/05/2024, 29 / 07 / 2024, 07/10/2024, 14/02/2025) Audit Committee Meetings were held.

➤ NOMINATION AND REMUNERATION COMMITTEE

The Company has a Nomination & Remuneration Committee of Directors in compliance with provisions of the Companies Act, 2013 and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Committee's scope of work includes nominate the directors as per their qualifications, experience and positive attributes, deciding on remuneration and policy matters related to remunerations of Directors and laying guidelines for remuneration package or compensation etc.

The Committee comprises of:

- Mr. Satendra Kumar Goyal (Non-Executive and Independent Director, Chairman)*.
- Mrs. Parul Agrawal (Non- Executive and Non-Independent Director).
- Mr. Ashok Kumar (Non- Executive and Non- Independent Director).

* Mr. Satendra Kumar Goyal was appointed as Independent Director on 09th May, 2024 and Mr Praveen Kumar Mishra resigned from the Independent Director on 28th August, 2024.

- During the year 04 Nomination and Remuneration Committee Meeting was held on 09/05/2024, 29 / 07 / 2024, 07/10/2024, 14/02/2025.



➤ STAKEHOLDERS & RELATIONSHIP COMMITTEE

The Company has a Stakeholder Relationship Committee of Directors in compliance with provisions of the Companies Act, 2013 and Regulation 20 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to look into the redressal of complaints of investors such as transfer or credit of shares, non-receipt of dividend/notices /annual reports, etc.

The Committee comprises of:

- Mr. Satendra Kumar Goyal (Non-Executive and Independent Director, Chairman)*.
- Mrs. Parul Agrawal (Non- Executive and Non-Independent Director).
- Mr. Ashok Kumar (Non- Executive and Non- Independent Director).

* Mr. Satendra Kumar Goyal was appointed as Independent Director on 09th May, 2024 and Mr Praveen Kumar Mishra resigned from the Independent Director on 28th August, 2024.

The Company has a Stakeholder Relationship Committee of directors to look into the redressal of complaints of investors such as transfer or credit of shares, non-receipt of dividend/notices /annual reports, etc.

During the year 01 Stakeholders & Relationship Committee Meeting was held on 14.02.2025.

➤ RISK MANAGEMENT COMMITTEE

The Company's Risk Management Committee comprises all the 1 Independent Directors and non-executive director.

The Committee comprises of:

- Mr. Satendra Kumar Goyal (Non-Executive and Independent Director, Chairman)*.
- Mrs. Parul Agrawal (Non- Executive and Non-Independent Director).
- Mr. Ashok Kumar (Non- Executive and Non- Independent Director).

* Mr. Satendra Kumar Goyal was appointed as Independent Director on 09th May, 2024 and Mr Praveen Kumar Mishra resigned from the Independent Director on 28th August, 2024.

- During the year 01 Risk Management Committee Meeting was held on 14.02.2025.

➤ INDEPENDENT DIRECTOR'S MEETING

During the year 2024-25, one meeting of Independent Directors was held on 12th June 2024.

DIRECTOR'S RESPONSIBILITY STATEMENT

Pursuant to the requirement of Section 134(5) of the Act, and based on the representations received from the management, the directors hereby confirm that:

- a) In the preparation of the annual accounts for the year ended March 31, 2025, the applicable accounting standards read with requirements set out under Schedule III to the Act, have been followed and there are no material departures from the same;
- b) we have selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31, 2025 and of the profit of the Company for the year ended on that date;
- c) we have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;



- d) we have prepared the annual accounts on a going concern' basis;
- e) we have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and
- f) we have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

MANAGEMENT'S DISCUSSION AND ANALYSIS

The Management Discussion and Analysis Report for the Financial Year 2024-25 as required under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is annexed to this Report as **Annexure – I**.

DECLARATION BY THE INDEPENDENT DIRECTOR

The Company has received declarations from all the Independent Directors of the Company confirming that they meet the criteria of independence as prescribed under the Companies Act, 2013 read with Regulations 16 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and that they are not disqualified from continuing their appointment as Independent Director.

During the year under review the non- executive directors of the company had no Pecuniary relationship or transactions with the Company other than sitting fees, commission, if any and reimbursement of expenses incurred for the purpose of attending the meetings of the board or committees of the company.

The Company has received requisite annual declarations/confirmations from all the aforesaid Independent Directors. The Board of Directors of the Company is of the view that Independent Directors fulfil the criteria of independence and they are independent from the management of the Company.

The Company has noted that the names of all Independent Directors have been included in the data bank maintained with the Indian Institute of Corporate Affairs, Manesar ('IICA'). Accordingly, all the Independent Directors of the Company have registered themselves with IICA for the said purpose. In terms of Section 150 of the Act read with the Companies (Appointment & Qualification of Directors) Rules, 2014, as amended thereof, both the Independent Directors are exempted from undertaking online proficiency self-assessment test conducted by the IICA.

PERFORMANCE EVALUATION

Pursuant to the provisions of the Companies Act, 2013 and Regulation 17(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a separate exercise was carried out to evaluate the performance of individual Directors, including the Chairman of the Board who were evaluated on parameters such as level of engagement and contribution and independence of judgment thereby safeguarding the interest of the Company.

The performance evaluation of the Independent Directors was carried out by the entire Board. The performance evaluation of the Chairman and the Non-Independent Directors was carried out by the Independent Directors. The board also carried out an annual performance evaluation of the working of its Audit, Nomination and Remuneration as well as stakeholder relationship committee. The Directors expressed their satisfaction with the evaluation process. The Board of Directors reviewed all the laws applicable to the company, prepared by the company and taking steps to rectify instances of non-compliances

PARTICULARS OF EMPLOYEES

None of the employees of the Company were in receipt of remuneration in excess of limits as prescribed under Rule 5 (2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

Disclosures pertaining to remuneration and other details as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, are mentioned below:



A. Information as per Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

Name of the Director/ and KMP	Designation	Remuneration (in Lakhs) 2024-25	Remuneration in Consideration	Resignation Dated
Mr. Yogesh Agrawal	Managing Director & CFO	-	-	-
Mr. Praveen Kumar Mishra	Non-Executive - Independent Director	-	-	28/08/2024
Mrs. Parul Agrawal	Non - Executive Non - Independent Director	-	-	-
Mr. Ashok Kumar	Non - Executive Non Independent Director	-	-	-
Mr. Ashok Kumar Khattar	Non-Executive and Independent Director	-	-	08/01/2025
Mr. Satendra Kumar Goyal	Non - Executive and Independent Director	-	-	-
Mrs. Anupam Aditya	Company Secretary & Compliance Officer	Rs. 1.80 Lakhs	-	-

RELATED PARTY TRANSACTIONS

In line with the requirements of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, your Company has formulated a Policy on Related Party Transactions which is also available on Company's website at www.genomicvalley.com. The Policy intends to ensure that proper reporting, approval and disclosure processes are in place for all transactions between the Company and Related Parties.

This Policy specifically deals with the review and approval of Material Related Party Transactions keeping in mind the potential or actual conflicts of interest that may arise because of entering into these transactions. Transactions with related parties as per AS – 18 have been disclosed in the notes forming part of Financial Statements. All Related Party Transactions are placed before the Audit Committee for review and approval. Prior omnibus approval is obtained for Related Party Transactions on a quarterly basis for transactions which are of repetitive nature and / or entered in the Ordinary Course of Business and are at Arm's Length. All Related Party Transactions are subjected to independent review by a reputed accounting firm to establish compliance with the requirements of Related Party Transactions under the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

All Related Party Transactions entered during the year were in Ordinary Course of the Business and on Arm's Length basis. No Material Related Party Transactions, i.e. transactions exceeding ten percent of the annual consolidated turnover as per the last audited financial statements, were entered during the year by your Company. Accordingly, the disclosure of Related Party Transactions as required under Section 134(3) (h) of the Companies Act, 2013 in Form AOC 2 is not applicable.

INTERNAL FINANCIAL CONTROL

The Board has adopted the policies and procedures for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial disclosures.

The Company's Internal Control Systems are commensurate with the nature of its business and the size and complexity of its operations. It comprises audit and compliance by internal auditor.

The Internal Auditors independently evaluate the adequacy of internal controls and concurrently audit the financial transactions and review various business processes. Independence of the Internal Auditors and therefore compliance is ensured by the direct report of internal audit division and Internal Auditors to the Audit Committee of the Board.



RISK MANAGEMENT

Pursuant to Section 134(3)(n) of the Companies Act, 2013, the Company has developed and implemented the Risk Management Policy for the Company including identification therein of elements of risk, if any, which is in the opinion of the Board may threaten the existence of the Company. These are discussed at the meeting of the Risk management committee and the Board of Directors of the Company.

At present the Company has not identified any element of risk which may threaten the existence of the Company.

PREVENTION OF INSIDER TRADING

The Company has a Code of Conduct for Prevention of Insider Trading with a view to regulate trading in securities by the Directors and certain designated employees of the Company. The Code requires pre-clearance for dealing in the Company's shares and prohibits the purchase or sale of Company shares by the Directors and designated employees while in possession of unpublished price sensitive information in relation to the Company and during the period when the trading window is closed. The Board is responsible for implementation of the Code. All Board Directors and the designated employees have confirmed compliance with the Code.

DISCLOSURE OF RELATIONSHIP BETWEEN DIRECTOR INTER-SE

Mrs. Parul Agrawal appointed as an Director (Non-executive and Non-Independent Director in the company is a wife of Mr. Yogesh Agrawal who is a Managing Director of the company.

SECRETARIAL STANDARDS

Your Company complies with the Secretarial Standard on Meetings of Directors (SS-1) and Secretarial Standard on General Meetings (SS-2) whenever it has applicable. Your Company will comply with the other Secretarial Standards issued by the Institute of Company Secretaries of India (ICSI) as and when they are made mandatory.

AUDITORS

➤ STATUTORY AUDITORS

M/s ANDROS & CO. (Firm Reg. No. 008976N), Chartered Accountants, was re-appointed as the Statutory Auditors of the Company at the Annual General Meeting held on 30th December 2024 for a term of five years, covering the financial years 2024-25 to 2028-29. They shall hold office from the conclusion of the 30th Annual General Meeting until the conclusion of the 35th Annual General Meeting, and their remuneration for the said period shall be fixed by the Board of Directors as per the agreed terms.

M/s Andros & Co. has conducted the Statutory Audit of the Company for the Financial Year 2024-25.

AUDITOR'S REPORT

The Auditor's Report for financial year ended March 31, 2025, does not contain any qualification, reservation or adverse remarks. All Observations made in the Independent Auditors' Report and Notes forming part of the Financial Statements are self-explanatory and do not call for any further comments and also, there is no incident of fraud requiring reporting by the auditors under section 143(12) of the Companies Act, 2013 during the year. The Auditor's report is enclosed with the financial statements in this Auditor's Report.

➤ SECRETARIAL AUDITORS

The Company has appointed SBR & Co. LLP, Company Secretaries as Secretarial Auditors of the Company for carrying out the secretarial audit for the financial year 2025-30.

The Secretarial Audit Report in Form MR-3 for the financial year ended March 31, 2025, is annexed herewith as **Annexure-II**. Secretarial Audit Report does not contain any qualification, reservation or adverse remark.



➤ INTERNAL AUDITOR

Mr. Navjyoti Kumar Jha has been appointed as Internal Auditors of the Company to conduct the Internal Audit of the company for the Financial Year 2024-25.

➤ COST AUDITORS

The Company has not appointed the Cost Auditor as pursuant to Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Amendment Rules, 2014, the cost audit is not applicable to the Company.

CORPORATE GOVERNANCE

As per Regulation 27(2) of the SEBI (LODR) Regulations, 2015 Corporate governance provisions are not applicable to a listed entity only if the paid-up equity share capital is less than Rs. 10 Crore and net-worth is less than Rs. 25 Crore. Since the company having Paid up capital is Rs. 3,05,45,000/- and Net Worth is Rs. 3,89,81,533/- which is not exceeding the limits as specified above. Therefore, the compliance with the Corporate Governance provision specified in the applicable Regulation shall not be applicable to the Company.

PREVENTION OF SEXUAL HARRASMENT

The Company is an equal opportunity provider and has zero tolerance in any form or manner towards the sexual harassment of women at work place. In accordance with the Sexual Harassment of Women at Work Place (Prevention, Prohibition and Redressal) Act, 2013, the Company has formulated a policy on prevention, prohibition and redressal of sexual harassment of women at work place. The Company has constituted Internal Complaints Committee which meets as and when required.

No complaints pertaining to sexual harassment of women employees were received during the year.

Sexual Harassment Complaints Report

Status of Complaints during the year	No. of Complaints
Number of complaints of Sexual Harassment pending at the beginning of the quarter	0
Number of complaints of Sexual Harassment received during the year	0
Number of complaints of Sexual Harassment disposed off during the year	0
Number of complaints / cases pending for more than 90 days	0

A STATEMENT BY THE COMPANY WITH RESPECT TO THE COMPLIANCE OF THE PROVISIONS RELATING TO THE MATERNITY BENEFIT ACT, 1961

There have been no claims for benefits by any female employees during the financial year 2024-25.

POLICY ON DIRECTORS'APPOINTMENT AND REMUNERATION& DISCHARGE OF THEIR DUTIES

A Nomination and Remuneration Committee has been constituted under section 178 of the Companies Act, 2013 for formulation the criteria for determining qualifications, positive attributes and independence of a Directors and recommend to the Board a policy relating to the remuneration for the Directors, Key Managerial Personnel and other employees. Further, the Directors of the Company are being paid remuneration as approved by the Shareholders and Board as per the provisions of the Act and rules made thereunder.



FORMAL ANNUAL EVALUATION

The Nomination and Remuneration Committee of the Company has formulated Evaluation Policy during the year, which was approved by the Board of Directors. The Policy provides for evaluation of the Board, the Committee of the Board and individual Directors, including the Chairperson of the Board. The policy provides that evaluation of the performance of the Board as a whole, Board Committees and Directors shall be carried out on an annual basis.

CAUTIONARY STATEMENT

Statements in the Annual Report, particularly those which relate to Management Discussion and Analysis, describing the Company's objectives, projections, estimates and expectations, may constitute 'forward looking statements' within the meaning of applicable laws and regulations. Although the expectations are based on reasonable assumptions, the actual results might differ.

APPLICABILITY OF THE INDIAN ACCOUNTING STANDARDS (IND AS)

The financial statements have been prepared in accordance with the Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015.

EXTRACT OF ANNUAL RETURN

Pursuant to the provisions of Section 92(3) and Section 134(3)(a) of the Companies Act, 2013, and the rules made thereunder, as amended from time to time, every Company shall place a copy of the annual return on the website of the Company, if any, and the web-link of such annual return shall be disclosed in the Board's report. The Annual Return, is due to be published, pending upgradation of the website of the Ministry of Corporate Affairs.

CORPORATE SOCIAL RESPONSIBILITY

Provisions relating to Corporate Social Responsibility enumerated under Section 135 of the Companies Act, 2013 was not applicable to the Company.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION & FOREIGN EXCHANGE EARNINGS & OUTGO

A. Conservation of Energy

The particulars as required under the provisions of Section 134(3)(m) of the Companies Act, 2013 in respect of conservation of energy and technology absorption have not been furnished considering the nature of activities undertaken by the company during the year under review. Expenditure on Power and fuel during the current financial year is as under:

Particulars	2024-25	2023-24
Expenditure on Power and fuel	NIL	NIL

However, the company at various intervals motivates their employees to conserve energy through regular reminders.

B. Technology Absorption

The company has made efforts to absorb the latest technology to minimize wastage.



C. Foreign Exchange earnings and Outgo

S. No.	Particulars	2024-25	2023-24
1.	Foreign Exchange Earnings	NIL	NIL
2.	Foreign Exchange Outgoings	NIL	NIL

HOLDING, SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES

During the year under review the company does not have any Holding, Subsidiaries, Joint Ventures and Associate Companies.

DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE

No such orders have been passed by any regulator or court or tribunal impacting the going concern status and company's operations in future.

VIGIL MECHANISM

Pursuant to Section 177(9) of the Act, a vigil mechanism was established for directors and employees to report to the management instances of unethical behaviour, actual or suspected, fraud or violation of the Company's code of conduct or ethics policy. The Vigil Mechanism provides a mechanism for employees of the Company to approach the Chief Ethics Counsellor / Chairman of the Audit Committee of Directors of the Company for redressal. No person has been denied access to the Chairman of the Audit Committee of Directors.

APPRECIATIONS AND ACKNOWLEDGMENTS

Your directors place on records their deep appreciation to employees at all levels for their hard work, dedication and commitment. The enthusiasm and unstinting efforts of the employees have enabled the Company to remain as industry leaders.

The Board places on record its appreciation for the support and co-operation your Company has been receiving from its suppliers, redistribution stockiest, retailers, business partners and others associated with the Company as its trading partners. Your Company looks upon them as partners in its progress and has shared with them the rewards of growth. It will be the Company's Endeavour to build and nurture strong links with the trade based on mutuality of benefits, respect for and co-operation with each other, consistent with consumer interests.

The Directors also take this opportunity to thank all Investors, Clients, Vendors, Banks, Government and Regulatory Authorities and Stock Exchanges, for their continued support.

For Genomic Valley Biotech Limited

Date: 08.12.2025

Place: Jhajjar

Sd/-

Yogesh Agrawal
Managing Director
DIN-0116528

Sd/-

Parul Agrawal
Director
DIN-0116518

**ANNEXURE-I****MANAGEMENT DISCUSSION & ANALYSIS REPORT**

In compliance of Regulation 34(3) and 54(f) read with Schedule V of Securities Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find Management Discussion and Analysis Report forming part of Annual Report.

1. OVERVIEW OF THE BUSINESS**Present Status**

The Company is providing consultancy in the Horticultural and Agricultural products. The company is also trading in Horticultural and Agricultural products. The company is also adding activities in Human Genomics.

Economy and Markets

India is among the top 12 destinations for biotechnology worldwide. The Department of Biotechnology (DBT), under the Ministry of Science and Technology, has placed great emphasis on developing an ecosystem for the development of excellence and research in a variety of biotechnology fields in India.

By creating and using a variety of tools at its disposal, such as vaccines, antivirals, diagnostic tests, and other tools, the biotechnology industry has been at the forefront of the fight against the Covid-19 pandemic. The pandemic has assisted the country in setting up the ideal ecosystem for production, sourcing, and exporting medical devices and vaccines.

India's bio-economy industry has grown from US\$ 10 billion in 2015 to US\$ 130 billion in 2024. India's bioeconomy contributes 2.6% to India's GDP, as of 2021. India's bioeconomy is poised to reach US\$ 300 billion by 2030.

Nearly a fifth of India's bioeconomy, standing at US\$ 14.56 billion, was due to the Covid-19 vaccination and testing drive. Covid-19 vaccines had a worth of US\$ 8.7 billion, whereas testing cost US\$ 5.9 billion. 1.45 billion Covid-19 doses were administered in 2021, and 1.3 million Covid tests were taken every day.

The largest portion of the Indian bioeconomy continues to be accounted for by biopharma. Biopharma accounted for 49% share of the bioeconomy, and its total economic contribution was estimated at US\$ 39.4 billion. By 2025, the vaccination market in India is projected to be worth Rs. 252 billion (US\$ 3.04 billion). In July 2022, India's 1st indigenously developed quadrivalent Human Papilloma Virus (qHPV) vaccine against Cervical cancer supported by DBT and BIRAC received market authorization from DCGI.

Industry Structure and Development

As you all know Honorable Prime Minister Shri Narendra Modi had explicitly stated in his election campaign that farmers would be the priority and the government would ensure they got 50% returns over their total costs. Keeping this in mind your company has started implementing measures to provide all round support to ensure a minimum return and also increase their production and earning multi-fold.

A. Agri Farming Consultancy:

With the expert team of agriculturists and other technical people, the company is also providing Agri Farming Consultancy to farmers and other clients on case - to - case basis. This way company is providing solutions to problems being faced by the HNI clients in agri-farming business as per their specific needs.

The Company's Agri Consultancy services aim to transform the agricultural sector by providing expert guidance and innovative solutions to address key challenges. Catering to farmers, agribusinesses, and policymakers, these services focus on enhancing productivity, sustainability, and profitability in agricultural practices.



The Company provides expert consultancy in high-tech cultivation techniques, enabling farmers and agribusinesses to adopt advanced agricultural practices for enhanced productivity and sustainability. These include environment-controlled polyhouses, which create optimal growing conditions by regulating temperature, humidity, and light, ensuring year-round cultivation with protection from adverse weather and pests. The consultancy also specializes in Nutrient Film Technique (NFT), a hydroponic method where a thin film of nutrient-rich water flows over plant roots, promoting efficient nutrient absorption and faster growth, ideal for leafy greens and herbs. Additionally, the Deep Flow Technique (DFT) offers a hydroponic system for larger crops like tomatoes and cucumbers, with roots submerged in nutrient-rich water for consistent nourishment. By leveraging these innovative techniques, the Company empowers clients to achieve higher yields, superior quality, and resource-efficient farming practices, catering to both domestic and export markets.

Key areas of focus include:

- Sustainable Farming Practices: Promoting eco-friendly methods that enhance soil health, conserve resources, and build resilience to climate change.
- Precision Agriculture: Employing advanced technologies like GPS mapping, satellite imagery, and IoT devices to optimize crop management and reduce waste.
- Resource Optimization: Offering strategies to maximize water, fertilizer, and input efficiency to achieve higher yields with minimal environmental impact.
- Agri-Tech Integration: Advocating the use of drones, robotics, and automation to modernize farming processes and increase operational efficiency.

The Company also provides personalized Agri Farming Consultancy through its team of expert agriculturists and technical professionals. These tailored solutions address the specific needs of clients, including High Net Worth Individuals (HNIs) involved in agri-farming businesses. By understanding their unique challenges, the Company delivers impactful, customized strategies that drive superior results and align with client objectives.

In addition to direct consultancy services, the Company plays a proactive role in knowledge sharing and capacity building by organizing workshops, seminars, and training programs. These initiatives are designed to educate farmers and stakeholders about the latest advancements in agricultural practices and technologies, empowering them to adopt innovative solutions effectively. This commitment to skill development further enhances the impact of the Company's efforts, fostering a culture of continuous improvement and innovation in the agricultural sector.

Through its comprehensive Agri Consultancy services, the Company empowers stakeholders with actionable insights and advanced tools, fostering long-term sustainability and economic growth. These efforts also contribute to environmental conservation, enabling the agricultural sector to evolve and thrive in a rapidly changing world.

B. Human Genomics: Advancing Personalized Healthcare:

The company intends to develop full packaging system and logistics to deliver fruits and vegetable direct to homes in NCR as per their daily demands and orders. The company is also working on to make it an online portal and also through mobile app to reach the masses and thus gathering increase orders and reach to more and more households. Thus, eliminating of middle man will reduce the cost and enhance the quality of fruits and vegetables.

The Company is a trailblazer in the field of Human Genomics, driving innovation in genetic research and personalized healthcare. By leveraging cutting-edge technologies such as Next-Generation Sequencing (NGS) and artificial intelligence (AI), the Company is addressing critical healthcare challenges and transforming patient care. This dynamic domain focuses on using advanced genomic and bioinformatics tools to enable early diagnosis, targeted therapies, and improved health outcomes.

Key offerings in this area include:

- **Genetic Testing and Analysis:** Comprehensive genetic profiling is conducted to uncover valuable insights into individual health risks and hereditary predispositions. By utilizing NGS technologies, the Company delivers accurate and detailed assessments that empower individuals and healthcare providers to make informed decisions about preventive and therapeutic measures.



- **Disease Screening and Prediction:** The Company's expertise enables the early detection and prevention of genetic disorders and complex diseases such as cancer, diabetes, and cardiovascular conditions. With advanced screening capabilities, individuals are provided with critical information to address potential health challenges proactively, significantly improving long-term outcomes.
- **Tailored Treatment Planning:** By analyzing genomic data, the Company develops highly personalized treatment strategies. This approach is particularly impactful in oncology, where precision medicine is essential for targeting specific genetic mutations. These tailored plans minimize adverse effects and maximize the effectiveness of therapies, setting a new standard for patient care.
- **Bioinformatics Solutions:** Leveraging powerful computational tools, the Company analyzes and interprets vast amounts of genomic data to unlock insights that drive both clinical applications and research innovation. This expertise ensures that the latest advancements in genomics are seamlessly integrated into healthcare practices, benefiting both researchers and practitioners.

Beyond its technical capabilities, the Company offers a comprehensive approach to empowering individuals and healthcare providers. Genetic counseling services help patients understand their genetic makeup and its implications for health and wellness. By fostering a deeper awareness of genomics, the Company plays a vital role in bridging the gap between cutting-edge science and practical, everyday healthcare solutions.

In addition to patient-focused services, the Company is actively involved in advancing research and contributing to global efforts to combat genetic disorders and complex diseases. Its contributions to precision medicine have positioned the Company as a leader in this rapidly evolving field, with a reputation for delivering high-quality, impactful solutions.

Furthermore, the Company invests in educational initiatives such as workshops and training programs to share its expertise with healthcare professionals, researchers, and academic institutions. By doing so, the Company not only enhances the capabilities of its partners but also strengthens its leadership in the genomics space.

C. Future Activities

1. Human Genomics and Precision Medicine:

- To advance research in human genomics to identify genetic variations and biomarkers associated with diseases.
- To develop personalized medicine strategies by leveraging AI-integrated genomic data analysis for better diagnosis and treatment.
- To enhance healthcare outcomes through genetic predisposition analysis and pharmacogenomics for personalized drug recommendations.

2. Plant Genomics for Sustainable Agriculture:

- To utilize genomic techniques for improving crop yield, resistance to diseases, and adaptation to environmental stresses.
- To integrate AI-based bioinformatics tools in plant genomics for efficient trait mapping and gene editing solutions.
- To collaborate with agricultural biotechnology firms to innovate sustainable and climate-resilient farming technologies.

3. Microbial Genomics and Metagenomics:

- To study microbial genomes and their applications in health, agriculture, and environmental sustainability.
- To advance metagenomic research to understand the human microbiome's role in health and disease, enabling the development of microbiome-based diagnostics and therapeutics.
- To promote microbial biotechnology for industrial applications such as bioremediation, fermentation, and biofuel production.

4. Strategic Partnerships:

- Signed an agreement with Artemis Hospital Gurgaon to leverage their state-of-the-art lab facilities for Next-Generation Sequencing (NGS) analysis.
- This collaboration enhances the precision and efficiency of genomic research and diagnostic services, supporting advancements in personalized medicine and cutting-edge genetic studies.
- In the later part, we will build an in-house state-of-the-art wet-lab facility for NGS and Molecular



Genetics for enhanced and timely data output and support. We would like to collaborate as a B2B partnership as well as a B2C approach for enhanced customer support for their analysis needs.

5. Bioinformatics and AI-Driven Genomic Solutions:

- To develop proprietary bioinformatics tools and software for genomic data analysis, visualization, and interpretation.
- To leverage AI and machine learning for accelerating genomic research and improving diagnostic accuracy.
- To create robust platforms for managing large-scale genomic datasets and facilitating global research collaborations.

6. Expanding Personalized Care Through Genetic Counseling:

- Comprehensive Genetic Counseling Services: Led by our esteemed Genetic Counselor and Consultant, these services help patients understand their genetic risks and plan preventive measures.
- Tailored Support for Diverse Needs: From assessing hereditary risks and managing rare diseases to exploring family planning options, our sessions provide personalized guidance for every individual.
- Empowering Informed Decisions: Our counseling ensures patients have the clarity and support needed to make well-informed decisions about their health and future.

7. Genomic Profiling and Ayurvedic Lifestyle Associations in Chronic Kidney Disease (CKD) in Gariaband, Chhattisgarh:

- Understanding Genetic Susceptibility: Identify and analyze genetic markers linked to CKD to provide individuals and families with insights into hereditary risks and potential preventive strategies.
- Tailored Interventions for Affected Populations: Offer specialized counseling and personalized healthcare plans based on genomic and environmental data to address CKD prevalence effectively.
- Empowering Communities with Knowledge: Educate communities and healthcare providers about CKD-related genetic factors, enabling early detection and informed decision-making for better health outcomes.

8. Community Health and Genomic Initiatives:

- To implement population-wide genetic screening programs for early disease detection and public health improvement.
- To design community health initiatives informed by genomic data to address region-specific health challenges.
- To educate and empower healthcare providers and the public on the benefits of genomic medicine.

9. Extramural and Collaborative Research:

- To participate in and support national and international research projects in genomics and biotechnology.
- To foster partnerships with academic institutions, research organizations, and industry leaders for mutual advancement in genomic sciences.
- To actively contribute to global efforts in genomic data sharing and standardization.

10. Innovation Hub for Biotechnology and Genomics:

- To establish GVBL as a global epicenter for genomics and biotechnology innovation inspired by the vision of creating a Silicon Valley of genomics in India.
- To create a multidisciplinary platform integrating genomics, AI, and IT for advancing healthcare, agriculture, and industrial biotechnology.
- To provide Research Process Outsourcing (RPO) services to support and accelerate global genomic research efforts.

11. Pharmaceutical Genomics and Biomanufacturing:

- To pioneer the integration of genomics in pharmaceutical development for targeted therapies.
- To establish scalable and efficient biomanufacturing processes for producing biologics and gene therapies.
- To contribute to global drug discovery efforts through genomic insights and AI-driven methodologies.

12. Research and Development:

- To lead innovations in all areas of human genomics, with a specific focus on identifying novel genetic biomarkers and therapeutic targets in oncology.



- To integrate Next-Generation Sequencing (NGS) with AI for rapid, precise, and cost-effective oncology diagnostics.
- To establish strategic collaborations with academic and industry leaders for translational cancer research.

13. Radiogenomic Innovations in Cancer Diagnosis and Treatment:

- Lead advancements in radiogenomics by integrating imaging and genomic data to enhance cancer diagnosis and personalized treatment strategies.
- Identify novel genetic biomarkers and therapeutic targets through radiogenomic analysis, with a specific focus on improving precision in oncology.
- Develop machine learning-driven models to correlate radiological features with genetic mutations, facilitating early detection and accurate classification of cancer subtypes.
- Create robust, user-friendly applications for clinical use, enabling healthcare providers to access predictive insights and optimize patient care.

D. Biotechnology Industry Growth

The growth of Biotechnology industry as per Transparency Market Research is estimated to observe substantial growth during 2010 and 2018 as investments from around the world are anticipated to rise, especially from emerging economical regions of the world. The report states that the global market for biotechnology, studied according to its application areas, shall grow at an average annual growth rate of CAGR 11.6% from 2012 to 2018 and reach a value worth USD 414.5 billion by the end of 2018. This market was valued approximately USD 216.5 billion in 2011. The market of bio agriculture, combined with that of bio seeds, is projected to reach a value worth USD 40.50 billion by 2024. The field of biopharmaceuticals dominated the global biotechnology market and accounted for 60% shares of it in the year 2011. Many biotechnological industries flourished by the technological advancements leading to new discoveries and rising demands from the pharmaceutical and agricultural sectors.

2. OPPORTUNITY AND THREATS

AGRICULTURE:

• Supply chain infrastructure

Technology-driven, integrated supply chains enable entities to reduce inventory and costs, add product value, extend resources, accelerate time to market, expand market, increase pricing for sellers and variety for buyers as well as retain customers. In order to have a successful supply chain, the Indian Government has sought to involve multiple stakeholders to improve interactions between farmers, processors, distributors and retailers. The nation's processed food industry is expected to grow to US\$ 958 billion by 2025 at a compound annual growth rate (CAGR) of 12%. The government's focus is on supply chain-related infrastructures like cold storage, abattoirs and food parks.

• Potential global outsourcing hubs

Huge opportunity exists for agri input segments like seeds and plant growth nutrients. According to the Center for Environment and Agriculture (CENTEGRO) and Crop Care Federation of India (CCFI), India can become the 'global agricultural hub' for other countries, which have harsh weather, scarce labour and lands, and are seeking to outsource their agriculture. There is a huge opportunity for agri-input segments such as seeds and nutrients for plant growth. To establish GVBL as a global epicenter for genomics and biotechnology innovation inspired by the vision of creating a Silicon Valley of genomics in India. To create a multidisciplinary platform integrating genomics, AI, and IT for advancing healthcare, agriculture, and industrial biotechnology. To provide Research Process Outsourcing (RPO) services to support and accelerate global genomic research efforts.

• Farm management services

Given the importance of agriculture in India, both the government and private players are working to improve the efficiency and productivity of Indian agriculture and exploring how Farming as a Service (FaaS) solutions can play a role. FaaS seeks to provide affordable technology solutions for efficient



farming. It converts fixed costs into variable costs for farmers, thus making the techniques more affordable for a majority of small farmers. Its services are available on a subscription or pay-per-use basis in 3 broad categories, which are crucial across the agriculture value chain.

BIOTECHNOLOGY

Biotechnology is one of the “hot spots” in research and development in this century. Great chances and opportunities lie ahead, but also tremendous threats. While technology and knowledge is easily available all over the world, it can be quite difficult to access markets and to commercialize biotechnological products.

Biotechnology, regardless of red, green or white biotechnology, promises high profits. However, the field is also complex, fast moving and costly. Especially in the field of medical applications there are many risks associated with biotechnology. One example is a drug developed against multiple sclerosis, which had possible profits of 3\$ billion.

After two patients developing a rare brain disease in clinical trials the profits vaporized and the stock market were in an uproar. Nevertheless, does the United Nations Development Program see “biotechnology innovation and globalization as a means of helping the poor of the world live fuller, richer and more secure lives”. Only through commercialization this promise will come true. Commercialization is converting or moving technology into a profit making position.

In our opinion the most important point is to bridge the gap between technology and markets. The matching of technological challenge and market challenge is difficult and many tools have been developed to address this problem.

In the Interim Budget 2024-25, the Department of Biotechnology (DBT) was allotted Rs. 2,251.52 crore (US\$ 271 million). India has potential for clinical trials due to a large and low-cost market. Clinical trials in India are regulated by the Central Drug Standard Control Organisation, which has reduced approval time to about 30-60 days, giving opportunity for market growth. Biofuels and bioenergy are considered alternative resources and are gaining popularity in India.

SUPPLY CHAIN

For providing diagnostics services for the Wet Lab, your company has the necessary understanding of the relevant companies and organizations for the purchase of the tissue culture production of your company.

Signed an agreement with Artemis Hospital Gurgaon to leverage their state-of-the-art lab facilities for Next-Generation Sequencing (NGS) analysis. This collaboration enhances the precision and efficiency of genomic research and diagnostic services, supporting advancements in personalized medicine and cutting-edge genetic studies. In the later part, we will build an in-house state-of-the-art wet lab facility for NGS and Molecular Genetics for enhanced and timely data output and support. We would like to collaborate as a B2B partnership as well as a B2C approach for enhanced customer support for their analysis needs.

Your Company's supply chain agenda remained focused on five key areas

1. Customer service excellence,
2. Consumer and customer quality,
3. End to end cash and cost savings program,
4. Leading with innovation, and
5. Technology and sustainability.

Your Company made significant progress in its vision to deliver customer service excellence to enable sustainable growth.

RESEARCH & DEVELOPMENT

To lead innovations in all areas of human genomics, with a specific focus on identifying novel genetic biomarkers and therapeutic targets in oncology. To integrate Next-Generation Sequencing (NGS) with AI for rapid, precise, and cost-effective oncology diagnostics. To establish strategic collaborations with academic and industry leaders for translational cancer research.



Our Research Team wishes to conduct Basic Research at the Premier Institute in the country in the following prospective fields:

Agriculture

- Crop Biotechnology
- Bio Fertilizers
- Bio Pesticides and Crop Management
- Plant Biotechnology

Plant Tissue Culture Micropagation

- Bio prospecting and Molecular taxonomy
- Bio fuels
- Medicinal and Aromatic Plants

Medical Biotechnology

- Vaccines
- Diagnostic
- Drug Development
- Human Genetics and Genome Analysis

3. COMPETITION:

We operate in a competitive atmosphere with multiple few organized competitors and multiple unorganized customers. There are no entry barriers in our industry which puts us to the threat of competition from new entrants. There are numerous players operating in the industry. We face tough competition in our business from a large number of unorganized and a few organized players. We believe that we have the potential to compete effectively in the market with our quality of products. We believe that the principal factors affecting competition in our business include client relationships, reputation, and the relative quality and price of the products. We compete with these competitors to enter directly into deals with customers.

4. PROSPECT & OUTLOOK

We are excited to announce a strategic collaboration with Artemis Hospital Gurgaon through the signing of an agreement to leverage their state-of-the-art laboratory facilities for Next-Generation Sequencing (NGS) analysis. This partnership enhances the precision and efficiency of genomic research and diagnostic services, driving advancements in personalized medicine and cutting-edge genetic studies. Looking ahead, we plan to establish an in-house, state-of-the-art wet-lab facility for NGS and Molecular Genetics, enabling enhanced and timely data output to meet the growing demands of the field. This initiative supports a dual approach: fostering B2B partnerships for collaborative research and tailored solutions while strengthening B2C services to provide personalized support for individual analysis needs. Together, these efforts position us as a leading player in genomic and molecular research, contributing to significant advancements in healthcare and science.

Environment, safety, Health and Energy Conservation

Your Company has a vision of being a 'Zero Injury' organization. The Compass, your Company's strategic framework, integrates Safety as a non-negotiable value. Over the past years, your Company has not reported any injuries across its operations.

This has been achieved through a combination of training and hardware upgradation leveraging core technology concepts and safety standards from the Company. Sustainability is deeply rooted in all the operations of your Company ranging from sourcing to Production and logistics. Your Company's aim is to achieve significant reduction in environmental impact of operations.

Your Company has used various majors for conservation of energy. Several efforts have been conferred by your Company in the spheres of Safety, Environment and Sustainability.



5. RISKS AND CONCERNS

There is a rich public debate about how the potential risks associated with biotechnology methods and bio industry products should be assessed and about whether and how bioethics should influence public policy. A general structure for guiding public policy discourse is emerging but is not fully developed. Groups perceive risks differently depending on their culture, scientific background, perception of government, and other factors. Expert opinion supports a range of positions. Deeply and honestly held but often conflicting beliefs and values about nature, animals, and the community good animate the debate. The result is that biotechnology issues are often highly contentious and debated on both scientific and ethical grounds. Two contemporary examples are:

- ❖ Do human social benefits such as living a longer and leading more productive life due to biotechnology outweigh the harm that an animal or groups of animals must experience to produce those benefits.
- ❖ Should an insurance company require information about an individual's genetic inheritance as a condition of eligibility for health insurance?

Biotechnology's risks are sometimes purely conjectural. Without research and clinical trials, risks cannot be fully assessed. Yet conjectural and ethical issues are important because biotechnology affects not only human practices and economic sectors, but also medical practices and the relationship between humanity, animals and the environment.

In Paul Thompson's view, [Biotechnology] is not simply another type of mechanical or chemical creation aimed at making the world better for us. In this instance, we are not simply reshaping matter, but are harnessing life. By manipulating life and natural evolution, we are taking the process that shaped our existence and that of every other living organism on the planet and restructuring it for our own benefit.

6. DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE

The details of the financial performance of your Company are reflected in the Balance Sheet, Profit & Loss Account and other Financial Statements, appearing separately. Highlights are provided below:

(In Rs.)

Particulars	Standalone
	2025
Revenue from Operations	84,39,394
Other Income	44,660
Total Income	84,84,054
Profit/(Loss) Before Tax	44,14,376

The financial performance of your Company has been further explained in the Directors' Report of your company for the year 2025, appearing separately.

7. ECONOMIC OUTLOOK

The long-term fundamentals of the Indian economy continue to be strong due to rising incomes and large investments. These growth drivers are expected to sustain over a long period of time. At the same time, there are some concerns due to uncertain global economic environment and slow recovery in developed markets.

8. HUMAN RESOURCES

The Company keeps developing its organizational structure consistently over time efforts are made to follow excellent Human Resource practices. Adequate efforts of the staff and management personnel are directed on imparting continuous training to improve the management practices. The objective of your company is to create a



workplace where every person can achieve his or her potential. The employees are encouraged to put in their best. Lots of hard work is put in to ensure that new and innovative ideas are given due consideration to achieve the short and long term objectives of your company.

The employees are satisfied and having good relationship with management.

9. CAUTIONARY STATEMENT

Certain statements in the Management Discussion and Analysis describing your Company's views about the industry, expectations/predictions, objectives etc. may be forward looking within the meaning of applicable laws and regulations. Actual results may differ from those expressed or implied in these statements. Your Company's operations may, inter-alia, be affected by the supply and demand situations, input prices and availability, changes in Government regulations, tax laws, government or court decisions and other factors such as industry relations and economic developments etc. Investors should bear this in mind when considering the above statements.

Internal control system

The company has started its commercial activity. However, the management is having highly professional outlook at the adequate control system during all its commercial activities.



Annexure-II

Form No. MR-3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED MARCH 31, 2025

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 09 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To,
The Member,
Genomic Valley Biotech Limited
CIN:- L01122HR1994PLC033029
4 K.M. Stone, Berri Chharr Road Vill.
Kherka, Musalman, P.O. Tandaheri Teh Bahadu,
Jhajjar, Haryana, India, 124507

I/ We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Genomic Valley Biotech Limited** (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided me/us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my/our verification of the Company **Genomic Valley Biotech Limited** books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorised representatives during the conduct of secretarial audit, I/we hereby report that in my/our opinion , the Company has , during the audit period covering the period ended on **March 31, 2025** complied with the Statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the extent, in the manner and subject to the reporting made hereinafter.

I/We have examined the books, papers, minute books, forms and returns filed and other records maintained by **Genomic Valley Biotech Limited** for the period ended on March 31, 2025 according to the provisions of;

1. The Companies Act, 2013 (the Act) and the rules made there under;
2. The Securities Contracts (Regulation) Act, 1956(SCRA) and the rules made there under;
3. The Depositories Act, 1996 and the Regulations and Bye-laws framed hereunder;
4. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment and Overseas Direct Investment and external commercial borrowings, The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India, 1992 ('SEBI Act');
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;
 - (d) The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014: **(Not applicable)**
 - (e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; **(Not applicable as the Company has not issued any further share**



capital during the period under review);

- (f) The Securities and Exchange Board of India (Registration to an Issue and Share Transfers Agents) Regulations, 1993;
- (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; **(Not Applicable as there was no reportable event during the period under review)**
- (h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998; **(not applicable as there was no reportable event during the period)**

5. The management has identified and confirmed the following laws as specifically applicable to the Company;

- i. Industrial Disputes Act, 1947
- ii. The Payment of Wages Act, 1936
- iii. The Minimum Wages Act, 1948
- iv. Employee State Insurance Act, 1948
- v. The Employee Provident Fund and Miscellaneous Provisions Act, 1952
- vi. The Payment of Bonus Act, 1965
- vii. The Payment of Gratuity Act, 1972
- viii. The Contract Labour (Regulation and Abolition) Act, 1970
- ix. The Maternity Benefits Act, 1961
- x. The Income Tax Act, 1961
- xi. Shops and Establishments Act, 1948
- xii. Legal Metrology Act, 2009

We have also examined compliance with the applicable clause of the following;

- I. The Secretarial Standards with regards to Meeting of Board of Directors (SS-1) and General meeting (SS-2) issued by The Institute of Company Secretary of India.
- II. SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Listing Agreements entered into by the Company with BSE Limited ~~and National Stock Exchange of India Limited~~.

During the period under review the Company has complied with the provisions of the Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors and a Women Director. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarification on the agenda items before the meeting and for meaningful participation at the meeting.

All the decisions of the Board and Committees thereof were carried out with requisite majority.



We further report that based on review of compliances mechanism established by the Company and on the basis of the Compliances Certificate issued by the Company Secretary and taken on record by the Board of Directors at their meetings. We are of the opinion that there are adequate systems and processes in the Company which is commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

As informed, the Company has responded appropriately to notices received from various statutory/regulatory authorities including initiating actions for corrective measures, wherever found necessary.

We further report that during the audit period there were no following specific events/actions having a major bearing on Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines standards, etc.

**For SBR & Co. LLP
(Company Secretaries)**

SD/-
CS Rohit Batham
Designated Partner
Mem. No. A37260
CP. No: 19095
UDIN: A037260G002252880
Peer Review No. 5318/2023

Place: Ghaziabad
Date: 06.12.2025



To
The Members,
Genomic Valley Biotech Limited
CIN L01122HR1994PLC033029
4 K.M. STONE, BERRI CHHARRA ROAD VILL.
KHERKA, MUSALMAN, P.O. TANDAHERI TEH BAHADU,
JHAJJAR, Haryana, India, 124507

Our Secretarial Audit Report of even date, for the financial year 2024-25 is to be read along with this letter.

Management's Responsibility

1. It is the responsibility of the management of the company to maintain secretarial records devise proper systems to ensure compliance with the provisions of all applicable laws and regulations and to ensure that the systems are adequate and operate effectively.

Auditor's Responsibility

2. Our responsibility is to express an opinion on these secretarial records, standards and procedures followed by the Company with respect to secretarial compliances.
3. We believe that audit evidence and information obtained from the Company's management is adequate and appropriate for us to provide a basis for our opinion.
4. Wherever required we have obtained the management's representation compliances of laws, rules and regulations and happening of events etc.

Disclaimer

5. The Secretarial Audit Report is neither as assurance as to the future viability of Company nor of the effectiveness with which the management has conducted the affairs of the Company.
6. We have not verified the correctness and appropriateness of financial records and books account of the company.

For SBR & CO. LLP
(Company Secretaries)

Sd/-
CS Rohit Batham
Designated Partner
Mem. No. A37260
CP. No: 19095
UDIN: A037260G002252880

Place: Ghaziabad
Date: 06.12.2025

**Annexure III****MANAGING DIRECTOR (MD) & CHIEF FINANCIAL OFFICER (CFO) CERTIFICATION**

To,
The Board of Directors
Genomic Valley Biotech Limited
4 KM Stone, Berri Chhara Road,
P.O. Tandaheri, Teh.- Bahadurgarh,
Distt. Jhajjar, Haryana-124507

I, Yogesh Agrawal, Managing Director of Genomic Valley Biotech Limited, to the best of our knowledge and belief hereby certify that:

- a) I have reviewed financial statements and the cash flow statement for the year ended March 31, 2025 and that to the best of our knowledge and belief:
 - i) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - ii) these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- b) There are, to the best of my knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.
- c) I accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the company pertaining to financial reporting and we have disclosed to the Auditors and the Audit and Risk Management Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps I have taken or propose to take to rectify these deficiencies.
- d) I have indicated to the Auditors and the Audit Committee:
 - i. significant changes in internal control over financial reporting during the year;
 - ii. significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - iii. instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

Sd/-

Yogesh Agrawal
Managing Director
DIN: 01165288
Address: G-74, G-Block, Pushkar Enclave, Paschim Vihar,
Delhi 110063

Date: 30.05.2025

Place: Delhi



CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

Annexure IV

[Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To,
The Members of
Genomic Valley Biotech Limited
(CIN: L01122HR1994PLC033029)
4 K.M. Stone, Berri Chharra Road Vill.,
P.O. Tandaheri, Teh. Bahadurgarh,
Distt. Jhajjar, Haryana-124507

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **Genomic Valley Biotech Limited** having **CIN: L01122HR1994PLC033029** and having registered office at **4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Teh. Bahadurgarh, Distt. Jhajjar, Haryana-124507** (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers.

We hereby certify that one of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March 2025 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority.

S. NO.	Full Name	DIN	Date of Appointment
1	Mr. Yogesh Agrawal	01165288	07/09/2015
2	Mr. Satendra Kumar Goyal	08767544	09/05/2024
3	Mrs. Parul Agrawal	01165188	14/02/2024
4	Mr. Ashok Kumar*	07647876	14/11/2023
5	Mr. Ashok Kumar Khattar**	00516458	06/12/2024
6	Mr. Praveen Kumar Mishra***	09165954	30/06/2023

*Mr. Ashok Kumar has not completed his KYC requirements and did not attend any Board Meeting of the Company during the year.

**Mr. Ashok Kumar Khattar resigned as director with effect from January 08, 2025.

***Mr. Praveen Kumar Mishra resigned as director with effect from August 28, 2024.

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.



For and on behalf of SBR & Co. LLP
Company Secretaries

Sd/-
CS Rohit Batham
Designated Partner
Mem. No. A37260
CP. No: 19095

UDIN: A037260G002254266
Peer Review No: 5318/2023

Place: Ghaziabad
Date: December 06, 2025



INDEPENDENT AUDITORS' REPORT

**TO THE MEMBERS OF
GENOMIC VALLEY BIOTECH LIMITED
REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS**

Opinion

We have audited the accompanying standalone financial statements of **GENOMIC VALLEY BIOTECH LIMITED** (“the Company”), which comprise the Balance Sheet as at 31 March 2025, the Statement of Profit and Loss (including Other Comprehensive Income), Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as “Financial Statements”).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 (“the Act”) in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2025, the loss including other comprehensive loss, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the *Auditors' Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's *Code of Ethics*. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Financial Statements and Auditors' Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Annual Report, but does not include the financial statements and our auditors' report thereon. The Annual Report is expected to be made available to us after the date of the auditors' report.

Our opinion on the financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

Management's Responsibilities for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Act, we give in the "**Annexure A**", a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books and proper returns adequate for the purposes of our audit have been received .
 - (c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Cash Flow Statement dealt with by this report are in agreement with the books of account and with the returns received from the branches not visited by us.
 - (d) In our opinion, the aforesaid financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended.
 - (e) On the basis of the written representations received from the directors as on 31 March 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2025 from being appointed as a director in terms of Section 164(2) of the Act.

(f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in “**Annexure B**”. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company’s internal financial controls over financial reporting.

(g) With respect to the other matters to be included in the Auditors’ Report in accordance with the requirements of Section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of Section 197 of the Act.

(h) With respect to the other matters to be included in the Auditors’ Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- i. The Company has no pending litigations which has impact on its financial position;
- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
- iii. There has been no delay in transferring amounts required to be transferred, to the Investor Education and Protection Fund by the Company.
- iv. (a)The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entities (“**Intermediaries**”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (“**Ultimate Beneficiaries**”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b)The management has represented, that, to the best of its knowledge and belief, no funds have been received by the Company from any person or entity, including foreign entity (“**Funding Parties**”), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“**Ultimate Beneficiaries**”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11 (e), as provided under (a) and (b) above, contain any material misstatement.

v. The Company has not declared or paid dividend during the year.

vi. Based on our examination which included test checks, the company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with and the audit trail has been preserved by the company as per the statutory requirements for record retention .

**For ANDROS & CO.
Chartered Accountants
Firm Regn.No.008976N**

sd/-
CA.BHAVUK GARG
Partner
M. No.502310

**Place: New Delhi
Date:30.05.2025**

ANNEXURE A TO THE INDEPENDENT AUDITORS' REPORT

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of **GENOMIC VALLEY BIOTECH LIMITED** of even date)

To the best of our information and according to the explanations provided to us by the Company and the books of account and records examined by us in the normal course of audit, we state that:

- i. (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
(B) The Company does not have any intangible assets, hence reporting under clause 3(i)(a)(B) of the Order is not applicable.
- (b) All the Property, Plant and Equipment have been physically verified by the Management during the year. There is a regular programme of verification, which, in our opinion, is reasonable, having regard to the size of the Company and the nature of its Property, Plant and Equipment. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
- (c) We report that, the title deeds of all the immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) disclosed in the financial statements included under Property, Plant and Equipment are held in the name of the Company as at the balance sheet date.
- (d) The Company has not revalued any of its Property, Plant and Equipment (including Right of Use assets) during the year .
- (e) No proceedings have been initiated during the year or are pending against the Company as at 31 March 2025 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.

- ii. (a) The inventory has been physically verified by the management at reasonable intervals. In our opinion, the coverage and procedure of such verification by the management is appropriate. No discrepancies of 10% or more between the physical stocks and book records in the aggregate for each class of inventory were noticed on such verification.
- (b) The Company has not been sanctioned any working capital limit by financial institution during the year.

- iii. The Company has not made any investment, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties, during the year, and hence reporting under clause 3(iii) of the Order is not applicable.
- iv. The Company has not entered into any transaction in respect of loans, investments, guarantees and security to which the provisions of Section 185 and 186 of the Act would apply.
- v. The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence, reporting under clause 3(v) of the Order is not applicable.
- vi. The maintenance of cost records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act for the business activities carried out by the Company. Hence, reporting under clause 3(vi) of the Order is not applicable to the Company.
- vii. (a) According to the records of the Company, the Company is regular in depositing with appropriate authorities undisputed statutory dues including Goods and Services Tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Customs, duty of Excise, Value Added Tax, Cess and any other statutory dues applicable to it, except in few cases where there is a delay in deposit. According to the information and explanations given to us, no undisputed amounts payable in respect of Goods and Services Tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service tax, duty of Customs, duty of Excise, Value Added Tax, Cess and any other statutory dues applicable to it were outstanding, as at 31 March 2025 for a period of more than six months from the date they became payable.
- viii. There were no transactions related to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).

ix. (a) The Company has not defaulted in the repayment of loans or other borrowings or in the payment of interest to banks and directors. According to the information and explanations given to us, loans from directors, which are repayable on demand and outstanding as at the year end, have not been demanded for repayment during the financial year ended 31 March 2025. The Company has not taken any loans or other borrowings from government, financial institution or any other lender.

(b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority during the year.

(c) The Company has not taken any term loan during the year and hence reporting under clause 3(ix)(c) of the Order is not applicable.

(d) On an overall examination of the financial statements of the Company, funds raised on short-term basis have, *prima facie*, not been used during the year for long-term purposes by the Company.

(e) The Company does not have any subsidiary, associate or joint venture Company and hence reporting under clause 3(ix)(e) and clause(ix)(f) of the Order are not applicable.

x. (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the Order is not applicable.

(b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x)(b) of the Order is not applicable.

xi. (a) During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instance of fraud by the Company or any fraud on the Company, noticed or reported during the year, nor have we been informed of such case by the Management.

(b) No report under sub-section (12) of section 143 of the Act has been filed in Form ADT- 4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year.

(c) According to the information and explanations given to us, the Company has not received any whistle-blower complaints during the year.

xii. The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable.

xiii. All transactions with the related parties are in compliance with Sections 177 and 188 of the Act and the details have been disclosed in Note 28 of the financial statements as required by the applicable accounting standards.

- xiv. (a) In our opinion, the Company has an adequate internal audit system commensurate with the size and nature of its business.
(b) We have considered, the internal audit reports for the year under audit, issued to the Company during the year.
- xv. In our opinion during the year the Company has not entered into any non-cash transactions with its directors or persons connected with its directors and hence provisions of section 192 of the Act are not applicable to the Company.
- xvi. (a) In our opinion, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a) to (c) of the Order are not applicable.
(b) In our opinion, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and accordingly reporting under clause 3(xvi)(d) of the Order is not applicable.
- xvii. The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- xviii. There has been no resignation of the statutory auditors of the Company during the year.
- xix. On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- xx. The provisions of Section 135 the Act relating to **Corporate Social Responsibility** are not applicable to the Company, and hence reporting under clause 3(xx)(a) and clause 3(xx)(b) of the Order are not applicable.
- xxi. This clause is not applicable and hence not reported as no adverse comments have been given by other auditors in CARO in other group companies .

For ANDROS & CO.
Chartered Accountants
Firm Regn.No.008976N

sd/-
CA.BHAVUK GARG
Partner
M. No.502310

Place: New Delhi
Date: 30.05.2025

ANNEXURE B TO THE INDEPENDENT AUDITORS' REPORT

(Referred to in paragraph 2(f) under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of **GENOMIC VALLEY BIOTECH LIMITED** of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Act

We have audited the internal financial controls over financial reporting of the Company as of 31 March 2025 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") issued by the ICAI. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note issued by the ICAI and the Standards on Auditing prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2025, based on the criteria for internal financial control over financial reporting established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the ICAI.

**For ANDROS & CO.
Chartered Accountants
Firm Regn.No.008976N**

sd/-
CA.BHAVUK GARG
Partner
M. No.502310

**Place: New Delhi
Date:30.05.2025**

GENOMIC VALLEY BIOTECH LIMITED

REGD. OFF: 4 K.M. STONE BERI CHHARA ROAD, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

Balance Sheet as at 31.03.2025

Particulars	Note No.	Figures as at the end of 31.03.2025	Figures as at the end of 31.03.2024
ASSETS			
Non Current Assets			
Property, plant and equipment	1	87,004	20,656
Capital work in progress		-	-
Other Intangible assets		-	-
Intangible assets under development		-	-
Financial assets		-	-
Investment		-	166,660
Loans & Advances	2	17,211,439	14,000,000
Security Deposits	3	50,000	50,000
Other financial assets		-	-
Deferred tax assets (Net)		-	-
Other non current assets		-	-
Total Non-Current Assets		17,348,443	14,237,316
Current Assets			
Inventories		2,842,425	-
Financial Assets:		-	-
Investments		-	-
Trade Receivables	4	22,144,945	25,301,145
Cash and Cash equivalents	5	228,976	22,844
Other Balances with banks	5	223,261	37,890
Loans & Advances		-	-
Other financial assets		-	-
Other Current assets	6	777,574	3,737,529
Total Current Assets		26,217,181	29,099,408
Total Assets		43,565,624	43,336,724
EQUITY AND LIABILITIES			
Equity			
Equity Share Capital	7	30,545,000	30,545,000
Other Equity	8	8,436,533	4,875,601
Total Equity		38,981,533	35,420,601
Non Current Liabilities			
Financial liabilities		-	-
Borrowings		-	-
Security Deposits		-	-
Other Financial liabilities		-	-
Deferred tax liabilities (Net)	9	5,283	1,840
Provisions		-	-
Other Non Current liabilities		-	-
Total Non Current Liabilities		5,283	1,840
Current Liabilities			
Financial liabilities		-	-
Borrowings		-	-
Trade Payables	10	97,280	6,019,146
Other Financials liabilities		2,654,338	-
Provisions	11	875,000	25,000
Other Current liabilities	12	952,190	1,870,137
Total Current Liabilities		4,578,808	7,914,283
TOTAL EQUITY AND LIABILITIES		43,565,624	43,336,724

AS PER OUR REPORT OF EVEN DATE ANNEXED

For ANDROS & CO.

CHARTERED ACCOUNTANTS

FRN : 008976N

For and on behalf of

GENOMIC VALLEY BIOTECH LIMITED

sd/-
(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

sd/-
Yogesh Agrawal
Managing Director & CFO
DIN-01165288

sd/-
Parul Agrawal
Director
DIN-01165188

DATE: 30.05.2025

PLACE: DELHI

UDIN : 25502310BMGUFM8369

sd/-
ANUPAM ADITYA
Company Secretary
PAN: - BNWPA4447H

GENOMIC VALLEY BIOTECH LIMITED
REGD. OFF: 4 K.M. STONE BERI CHHARA ROAD, TEHSIL BAHADURGARH, DISTT. JHAIJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

Profit & Loss statement for year ended 31.03.2025

Particulars	Note No.	Figures for the year ending 31.03.2025	Figures for the year ending 31.03.2024
I. Revenue from Operations	13	8,439,394	1,650,750
II. Other Income	14	44,660	15,003
III. Total Revenue (I + II)		8,484,054	1,665,753
IV. Expenses:			
Cost of materials consumed		-	-
Purchases of Stock-in-Trade		4,856,220	-
Changes in inventories of finished goods work-in-progress and Stock-in-Trade		-2,842,425	-
Employee benefits expense	15	1,208,645	375,000
Finance costs		-	-
Depreciation and amortization expense	16	25,414	10,925
Other expenses	17	821,824	1,128,348
Total expenses		4,069,678	1,514,273
V. Profit before exceptional and extraordinary items and tax (III-IV)		4,414,376	151,480
VI. Exceptional items		-	-
VII. Profit before extraordinary items and tax (V - VI)		4,414,376	151,480
VIII. Extraordinary Items		-	-
IX. Profit before tax (VII- VIII)		4,414,376	151,480
X Tax Expense:			
(1) Current tax		850,000	-
(2) Deferred tax		3,444	-339
XI Profit (Loss) for the period from continuing operations (VII-VIII)		3,560,932	151,818
XII Profit/(loss) from discontinuing operations		-	-
XIII Tax expense of discontinuing operations		-	-
XIV Profit/(loss) from Discontinuing Operations (after tax) (XII-XIII)		-	-
XV Profit (Loss) for the period (XI + XIV)		3,560,932	151,818
XVI Earnings per equity share:			
(1) Basic		1.17	0.05
(2) Diluted		1.17	0.05

AS PER OUR REPORT OF EVEN DATE ANNEXED

For ANDROS & CO.
 CHARTERED ACCOUNTANTS
 FRN : 008976N

For and on behalf of
 GENOMIC VALLEY BIOTECH LIMITED

sd/-
 (CA Bhavuk Garg)
 (Partnership Firm)
 (Membership No.-502310)

sd/-
 Yogesh Agrawal
 Managing Director & CFO
 DIN-01165288

sd/-
 Parul Agrawal
 Director
 DIN-01165188

DATE: 30.05.2025
 PLACE: DELHI

sd/-
 ANUPAM ADITYA
 Company Secretary
 PAN:- BNWPA4447H

UDIN : 25502310BMGUFM8369

GENOMIC VALLEY BIOTECH LIMITED

REGD. OFF: 4 K.M. STONE BERI CHHARA ROAD, TEHSIL BAHADURGARH, DISTT. JHAIJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

CASH FLOW STATEMENT FOR THE YEAR ENDED 31.03.2025

	Particulars	Amount in INR	
		31.03.2025	31.03.2024
A.	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit As Statement Profit & Loss	4,414,376	151,480
	Adjustment For		
	Discount Received	-	-
	Non-Operating Income	-44,660	-15,003
	Interest Income	-	-
	Loss on sale of assets	-	-
	Depreciation	25,414	10,925
	Operating Profit Before Change in Working Capital	4,395,130	147,402
	ADJUSTMENTS FOR WORKING CAPITAL:		
	Increase/Decrease in Loans and Advances	-3,211,439	4,350,593
	(Increase)/Decrease in Inventories	-2,842,425	-
	Increase/Decrease in Security Deposits	-	-
	Increase/Decrease in Trade Receivables	3,156,200	-3,126,320
	Increase/Decrease in Other Current Assets	2,959,955	-553,708
	Increase/Decrease in Current Liabilities	-3,335,476	-1,018,669
	CASH GENERATED FROM OPERATIONS	1,121,945	-200,702
	Taxes Paid	853,444	-
	Total (a)	268,502	-200,702
B.	CASH FLOW FROM INVESTING ACTIVITIES		
	Additions/Sales to fixed assets	-91,763	-
	Purchase/Sell of Investments	166,660	-166,660
	Discount Received	-	-
	Non-Operating Income	44,660	15,003
	Interest Income	-	-
		119,557	-151,657
C.	CASH FLOWS FROM FINANCING ACTIVITIES		
	Proceeds from Borrowings	-	-
	Preliminary Expenses	-	-
	total (C)	-	-
	NET CASH FLOWS DURING THE YEAR (A+B+C)	388,059	-352,358
	Cash and Cash Equivalents (Opening Balance)	60,734	413,092
	Cash and Cash Equivalents (Closing Balance)	452,237	60,734

AS PER OUR REPORT OF EVEN DATE ANNEXED

For ANDROS & CO.

CHARTERED ACCOUNTANTS

FRN : 008976N

For and on behalf of

GENOMIC VALLEY BIOTECH LIMITED

sd/-

(CA Bhavuk Garg)

(Partnership Firm)

(Membership No.-502310)

sd/-

Yogesh Agrawal

Managing Director & CFO

DIN-01165288

sd/-

Parul Agrawal

Director

DIN-01165188

sd/-

ANUPAM ADITYA

Company Secretary

PAN:- BNWPA4447H

DATE: 30.05.2025

PLACE: DELHI

UDIN : 25502310BMGUFM8369

GENOMIC VALLEY BIOTECH LIMITED
REGD. OFF: 4 K.M. STONE BERI CHHARA ROAD, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507
NOTES TO ACCOUNTS YEAR ENDED 31.03.2025
CIN: L01122HR1994PLC033029

Note 7 Equity Share Capital

Share Capital	As at 31 March 2025		As at 31 March 2024	
	Number		Number	
Authorised				
Equity Shares of Rs 10 each	9,000,000	90,000,000	9,000,000	90,000,000
Issued				
Equity Shares of Rs 10 each	8,150,000	81,500,000	8,150,000	81,500,000
Subscribed				
Equity Shares of Rs 10 each	7,697,300	-	7,697,300	-
Less: Share Foreiture	4,642,800	-	4,642,800	-
Balances Shares of Rs 10 each	3,054,500	30,545,000	3,054,500	30,545,000
Paid up Capital				
Equity Shares of Rs 10 each Fully paidup	3,054,500	30,545,000	3,054,500	30,545,000
Total	3,054,500	30,545,000	3,054,500	30,545,000

List of shareholders holding more than 5 % shares

Particular	As at 31 March 2025		As at 31 March 2024	
	No. of shares	%	No. of shares	%
Yogesh Agrawal	1,427,000	46.72%	1,675,300	54.85%
Deepti Agrawal	336,000	11.00%	336,000	11.00%
VIKRAM ASHOKKUMAR JAIN	168,100	5.50%	0	0.00%
Harish Chandra sharma	0	0.00%	147,000	4.81%
Parul Agrawal	0	0.00%	283,700	9.29%
Amar Agrawal	276,510	9.05%	276,510	9.05%

Reconciliation of number of shares outstanding is set out below:

Particulars	As at 31 March 2025		As at 31 March 2024
	No. of shares	No. of shares	
Equity shares at the beginning of the year	3,054,500	3,054,500	
Add: Shares issued during the current financial year	-	-	
Equity shares at the end of the year	3,054,500	3,054,500	

Shares held by promoters at the end of the year 31st March 2025			% Change during the year
Promoter Name	No. of Shares	% of total shares	

Yogesh Agrawal	1,427,000	46.72%	-14.82%
Parul Agrawal	0	0.00%	-100.00
Ojaswani Avantika	0	0.00%	-100.00
Total	1,427,000	46.72%	

Shares held by promoters at the end of the year ending 31st March 2024			% Change during the year
Promoter Name	No. of Shares	% of total shares	
Yogesh Agrawal	1,675,300	57.82%	-5.150
Parul Agrawal	283,700	9.29%	0.00
Ojaswani Avantika	2,000	0.07%	0.07
Total	1,961,000	67.18%	

Note 8 Other Equity

	As at 31 March 2025	As at 31 March 2024
Reserves		
Subsidy for Green House	70,000	70,000
Sugarcane Development Fund	1,000,000	1,000,000
Share Forefeiture	11,607,000	11,607,000
Misc. Expenditure	-10,211,019	-10,211,019
	Total	2,465,981.00
Surplus		
Opening balance	2,409,620	2,257,801.34
Net Profit/Loss of Current Year	3,560,932	151,818.39
	Total	5,970,552
		2,409,619.73
	Total	8,436,533.05
		4,875,600.62

Note 9 Deferred tax liabilities (Net)

	As at 31 March 2025	As at 31 March 2024
Deferred tax liabilities (Net)	5,283	1,840
	Total	5,283
		1,840

Note 10 Trades Payable

Particulars	As at 31 March 2025	As at 31 March 2024
Total outstanding dues of micro enterprises and small enterprises	-	
Total outstanding dues of creditors other than micro enterprises and small enterprises	97,280	6,019,146

Total	97,280	6,019,146
--------------	---------------	------------------

Note 10.1 : Steps have been taken to identify the suppliers who qualify under the definition of micro and small enterprises, as defined under the Micro, Small and Medium Enterprises Development Act 2006. Since no intimation has been received from the suppliers regarding their status under the said Act as at 31st March 2025, disclosures relating to amounts unpaid as at the year end, if any, have not been furnished. In the opinion of the management, the impact of interest, if any, that may be payable in accordance with the provisions of the Act, is not expected to be material.

Trade Payables ageing schedule: As at 31st March,2025

Particulars	Outstanding for following periods from due date of payment			
	Less than 1 year	1-2 years	2-3 years	More than 3 years
(i) MSME				
(ii) Others	97,280			
(iii) Disputed dues- MSME				
(iv) Disputed dues - Others				

Trade Payables ageing schedule: As at 31st March 2024

Particulars	Outstanding for following periods from due date of payment			
	Less than 1 year	1-2 years	2-3 years	More than 3 years
(i) MSME				
(ii) Others	6,019,146			
(iii) Disputed dues- MSME				
(iv) Disputed dues - Others				

Note 11 Provisions

	As at 31 March 2025	As at 31 March 2024
Audit Fees payable	25,000	25,000
Provision for Income Tax	850,000	0
Total	875,000	25,000

Note 12 Other Current Liabilities

	As at 31 March 2025	As at 31 March 2024
Yogesh Agrawal-Imprest	532,754	1,864,137
GST Payable	281,436	0
Salary Payable	138,000	0
TDS Payable	0	6,000

Total	952,190	1,870,137
--------------	----------------	------------------

Note 1 Property Plant and Equipments

Assets	Land & Building	Plant & Equipment	Computers	Green house	Total
Gross Block					
Balance as at March 31, 2023	0	2,932,512	34,500	1,824,065	4,791,077
Additions	0	0	0	0	0
Deletions	0	-2,932,512	0	-1,824,065	-4,756,577
Balance as at March 31, 2024	0	0	34,500	0	34,500
Additions	0	0	91,763	0	91,763
Deletions	0	0	0	0	0
Balance as at March 31, 2025	0	0	126,263	0	126,263
Accumulated Depreciation					
Balance as at March 31, 2023	0	2,932,512	2,919	1,824,065	4,759,496
Additions	0	0	10,925	0	10,925
Deletions	0	-2,932,512	0	-1,824,065	-4,756,577
Balance as at March 31, 2024	0	0	13,844	0	13,844
Additions	0	0	25,414	0	25,414
Deletions	0	0	0	0	0
Balance as at March 31, 2025	0	0	39,258	0	39,258
Net Block					
Balance as at March 31, 2024	0	0	20,656	0	20,656
Balance as at March 31, 2025	0	0	87,004	0	87,004

Note 2 Loans & Advances

	As at 31 March 2025	As at 31 March 2024
Dr. Amit Chaurasia	200,000	0
New Victoria Hotel South India	7,921,633	0
Sri Hanuman Lorry Supply Office	89,806	0
Advance for corporate office	9,000,000	14,000,000
Total	17,211,439	14,000,000

Note 3 Security Deposits

	As at 31 March 2025	As at 31 March 2024
Netafim Security Deposit	50,000	50,000
Total	50,000	50,000

Note 4 Trade Receivables

Particulars	-	-
--------------------	----------	----------

<u>Outstanding for more than six months</u>		
a) Secured, considered good		
b) Unsecured, considered good		
c) Doubtful		
<u>Others</u>		
a) Secured, considered good	22,144,945	25,301,145
b) Unsecured, considered good		
c) Doubtful		
Total	22,144,945	25,301,145

Trade Receivables ageing schedule as at 31st March,2025

Particulars	Outstanding for following periods from due date of payment				
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years
(i) Undisputed Trade receivables -considered good			22,144,945.00		
(i) Undisputed Trade receivables -considered doubtful					
(iii) Disputed trade receivables considered good					
(iv) Disputed trade receivables considered doubtful					

Trade Receivables ageing schedule as at 31st March,2024

Particulars	Outstanding for following periods from due date of payment				
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years
(i) Undisputed Trade receivables -considered good		25,301,145			
(i) Undisputed Trade receivables -considered doubtful					
(iii) Disputed trade receivables considered good					
(iv) Disputed trade receivables considered doubtful					

Note 5 CASH AND CASH EQUIVALENTS

	As at 31 March 2025	As at 31 March 2024
a. Balances with banks		
In current a/c-Kotak	209,021	0
In current a/c-DCB	14,240	37,890
	223,261	37,890
b. Cash in hand		
	228,976	22,844
Total	452,237	60,734

Note 6 Other Current Assets

	As at 31 March 2025	As at 31 March 2024
Input Credit-GST	0	15,999
Advance paid to suppliers	0	2,500,000
TDS Receivable AY 2025-26	300,414	0
TDS Receivable AY 2024-25	0	63,038
TDS Receivable AY 2023-24	0	681,332
TDS Receivable AY 2020-21	477,160	477,160

Total	777,574	3,737,529
--------------	----------------	------------------

Note 13 Revenue From Operation

	As at 31 March 2025	As at 31 March 2024
Sales & Services	8,439,394	1,650,750
Total	8,439,394	1,650,750

Note 14 Other Income

	As at 31 March 2025	As at 31 March 2024
Interest Received	7,861	0
Intt On IT Refund	36,799	3
Prior Period	0	15,000
Total	44,660	15,003

Note 15 Employee benefits expense

	As at 31 March 2025	As at 31 March 2024
Salary	1,208,645	375,000
Total	1,208,645	375,000

Note 16 Depreciation

	As at 31 March 2025	As at 31 March 2024
Depreciation	25,414	10,925
Total	25,414	10,925

Note 17 Other Expenses

	As at 31 March 2025	As at 31 March 2024
AGM Expenses	2,200	2,200
Audit Fee	25,000	25,000
Bad Debts W/off	0	21,972
Bank Charges	1,552	1,694
BSE Listing FEE	325,000	325,000
CDSL FEE	20,000	21,362
CONVEYANCE	6,400	5,610
Computer maintenance Exp.	3,000	0
Courier Expenses	0	7,260
Director's Fees Meeting	30,000	120,000
GST/TDS Late Fees and Intt	2,589	40,662
Interest Paid-TDS	0	4,779
Legal & Profession Expense	131,000	393,000
Legal & Roc Expenses	60,000	53,800
Misc. Expenses	25,993	978
News Paper Advertisement	27,360	42,840
NSDL fees	9,000	10,018
Office Expenses/Rent	92,993	12,000
Printing Stationery and Postal Expenses	14,150	9,990
Repair & Maintanance	2,300	3,605
RTA Fee	26,326	18,338
Round off	1	0

Staff Welfare Expense	16,960	3,840
Website Expense	0	4,400
Total	821,824	1,128,348